RU2575615C2 - Pcv2 immunogenic compositions and methods for producing these compositions - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, virology and veterinary science. The invention discloses the use of immunogenic compositions containing the PCV2 ORF2 recombinant protein, for inducing an immune response to PCV2 or producing a medicinal agent for inducing an immune response to PCV2. The amount of the PCV2 ORF2 recombinant protein in the composition makes at least 2 mcg. The presented invention can be used in veterinary science.

EFFECT: producing the new composition for veterinary science.

19 cl, 3 dwg, 24 tbl, 5 ex

Description

RELATED APPLICATIONS

This application claims the priority of provisional application number 60/640510, filed December 30, 2004, and application number 11/034737, filed January 13, 2005, the disclosure and contents of which are incorporated herein by reference.

LIST OF SEQUENCES

The application contains a list of sequences in paper format and in a computer-readable format, the explanations and contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Field of Invention

In one aspect, the present invention relates to the isolation of a protein expressed from an open reading frame 2 (ORF2) of pig type 2 circovirus (PCV2). More specifically, the protein is a recombinant protein expressed by a transfected virus containing recombinant coding sequences for pig type 2 circovirus, an open reading frame 2. Still more specifically, a transfected virus is allowed to infect cells in a culture medium, and a protein expressed from an open reading frame 2 , isolated from the supernatant, and not from the inner space of the cells. Even more specifically, the method includes the steps of amplifying an open reading frame 2 gene from pig type 2 circovirus, cloning this amplified part into a first vector, cutting out the open reading frame 2 part from this vector, and cloning into a transfer vector, cotransfection of cells in the culture medium with a viral vector transfer vector, allowing cells to be infected with the viral vector and thereby expressing the open reading frame 2, and isolating the expressed recombinant protein, encoded by open reading frame 2, from the supernatant.

In another aspect, the present invention relates to an immunogenic composition effective for inducing an immune response against PCV2, and methods for producing these immunogenic compositions. More specifically, the present invention relates to an immunological composition effective to provide an immune response that protects the animal to which the composition has been administered and reduces or reduces the severity of the clinical symptoms associated with PCV2 infection. Even more specifically, the present invention relates to a protein-based immunological composition providing effective protection against PCV2 infection. Even more specifically, the present invention relates to an immunological composition comprising ORF2 from PCV2, where administration of PCV2-ORF2 leads to protection against PCV2 infection. Most specifically, the present invention relates to an immunological composition effective to provide effective immunity in a pig, which is administered an immunological composition, where the composition contains a protein expressed with ORF2 from PCV2.

Description of the prior art

Swine circovirus type 2 (PCV2) is a small (17-22 nm in diameter), icosahedral DNA virus without an outer shell containing a single-stranded ring genome. PCV2 shares approximately 80% of the identical sequence with pig type 1 circovirus (PCV1). However, unlike PCV1, which is usually not virulent, pigs infected with PCV2 show a syndrome with the common designation multisystem exhaustion syndrome after weaning from sows (PMWS). PMWS are clinically characterized by wasting, pallor, frailty, respiratory problems, diarrhea, jaundice and spillage of bile. In some affected pigs, a combination of all the symptoms is observed, while in other pigs, only one or two of these symptoms are observed. At autopsy, damage is also found in many tissues and organs, where the lymphoid organs are the primary lesion sites. A strong correlation was found between the amount of nucleic acid or PCV2 antigen and the severity of microscopic lymphoid lesions. The mortality rate for pigs infected with PCV2 can reach 80%. In addition to PMWS, PCV2 is associated with several other infections, including pseudorabies, porcine respiratory reproductive syndrome (PRRS), Glasser disease, streptococcal meningitis, salmonellosis, sowing colibacillosis, dietary hepatosis and purulent bronchopneumonia.

An open reading frame protein 2 (ORF2) of PCV2 having an approximate molecular weight of 30 kDa when passing the SDS-PAGE gel was used in the past as an antigenic component of PCV2 vaccines. Conventional methods for producing ORF2 for use in such vaccines typically consist of amplification of PCV2 DNA encoding ORF2, transfection of the viral vector of DNA ORF2, infection of cells with a viral vector containing ORF2 DNA, allowing the virus to express the ORF2 protein in the cell and isolating the ORF2 protein from cells by cell lysis. These methods typically take up to about four days after infection of the cells with a viral vector. However, these methods have the disadvantage that the isolation methods are both expensive and time consuming. In addition, the amount of ORF2 isolated from the cells is not very large; therefore, it is necessary to infect a large number of cells with a large number of viral vectors in order to obtain sufficient amounts of expressed recombinant protein for use in vaccines and the like.

Current methods for immunizing PCV2 include DNA-based vaccines, such as those described in US Pat. No. 6,703,023. However, such vaccines have been ineffective in providing protective immunity against PCV2 infection and related clinical signs.

Accordingly, in this area there was a need for a method of producing an ORF2 protein that does not require isolation of the ORF2 protein from the interior of infected cells. In addition, there was a need for methods for producing a recombinant protein ORF2 in quantities sufficient to effectively obtain a vaccine composition. In addition, there was still a need for methods for producing ORF2 protein that did not require the complex and laborious methods required for existing methods for isolating ORF2 protein. Finally, with respect to the compositions, there has been a need in the art for an immunogenic composition that provides protective immunity against PCV2 infection and reduces the severity of associated clinical signs or prevents them.

SUMMARY OF THE INVENTION

The present invention overcomes the problems inherent in the prior art and provides a certain advantage in this field of knowledge. Specifically, in one aspect, the present invention relates to improved methods for producing and / or isolating a recombinant PCV2 ORF2 protein, i) by allowing infection of susceptible cells in culture with a recombinant viral vector containing the PCV2 ORF2 DNA coding sequence, where the ORF2 protein is expressed by a recombinant viral vector and ii) subsequent isolation of ORF2 from the supernatant. Surprisingly, ORF2 was released into the supernatant in large quantities if infection and subsequent incubation of the infected cells were allowed to proceed longer than in the conventional prior method for producing ORF2 PCV2, in which ORF2 PCV2 was isolated from the interior of the cells. Moreover, surprisingly, it was found that the PCV ORF2 protein is resistant to prototype degradation outside of producing cells. Both discoveries together allow the isolation of large amounts of PCV2 ORF2 protein from cell culture supernatant infected with recombinant viral vectors containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein. Large quantities of PCV2 ORF2 protein mean more than about 20 μg / ml supernatant, preferably more than about 25 μg / ml, even more preferably more than about 30 μg / ml, even more preferably more than about 40 μg / ml, even more preferably more than about 50 μg / ml, even more preferably more than about 60 μg / ml, even more preferably more than about 80 μg / ml, even more preferably more than about 100 μg / ml, even more preferably more than about 150 ug / ml, most preferably greater than about 190 ug / ml. Such expression levels can also be achieved, for example, by methods as described in Examples 1-3.

Preferred cell cultures have a cell number between about 0.3-2.0 × 10 ⁶ cells / ml, more preferably from about 0.35-1.9 × 10 ⁶ cells / ml, even more preferably from about 0.4 -1.8 × 10 ⁶ cells / ml, even more preferably from about 0.45-1.7 × 10 ⁶ cells / ml, and most preferably, from about 0.5-1.5 × 10 ⁶ cells / ml . One of skill in the art can determine preferred cells. Preferred cells are infection susceptible with a suitable recombinant viral vector containing PCV2 ORF2 DNA, and PCV2 expressing ORF2 protein. Preferably, the cells are insect cells, and more preferably, they include insect cells sold under the trade name Sf + insect cells (Protein Sciences Corporation, Meriden, CT).

Those skilled in the art can also determine a suitable culture medium, where a serum-free medium for insect cells, such as Excell 420 (JRH Biosciences, Inc., Lenexa, KS) and the like, is the preferred culture medium. Preferred viral vectors include baculoviruses such as BaculoGold (BD Biosciences Pharmingen, San Diego, CA), especially if the producing cells are insect cells. Although a baculovirus expression system is preferred, those skilled in the art will recognize that other expression systems are suitable for the purposes of the present invention, namely, the expression of PCV2 ORF2 in a cell culture supernatant. Such other expression systems may require the use of a signal sequence to induce the expression of ORF2 in the medium. Surprisingly, when ORF2 is obtained in a baculovirus expression system, no signal sequence or further modification is required to induce the expression of ORF2 into the medium. It is believed that this protein can independently form virus-like particles (Journal of General Virology Vol. 81, pp. 2281-2287 (2000)) and secrete into the culture supernatant. A recombinant viral vector containing PCV2 ORF2 DNA sequences has a preferred infection multiplicity (MOI) of between about 0.03-1.5, more preferably from about 0.05 to 1.3, even more preferably from about 0.09 to 1.1, and most preferably, from about 0.1 to 1.0 when used for infection of sensitive cells. Preferably, the above MOIs refer to one ml of culture fluid. Preferably, the method described herein includes an infection of 0.35-1.9 × 10 ⁶ cells / ml, even more preferably approximately 0.4-1.8 × 10 ⁶ cells / ml, even more preferably approximately 0.45 -1.7 × 10 ⁶ cells / ml, and most preferably, about 0.5-1.5 × 10 ⁶ cells / ml, a recombinant viral vector containing PCV2 ORF2 DNA and expressing PCV2 ORF protein having a MOI (multiplicity of infection) of approximately between 0.03-1.5, more preferably from about 0.05 to 1.3, even more preferably from about 0.09 to 1.1, and most preferably desirably, from about 0.1 to 1.0.

The infected cells are then incubated for up to ten days, more preferably from about two days to about ten days, even more preferably from about four days to about nine days, and most preferably from about five days to about eight days. Preferred incubation conditions include a temperature of between about 22-32 ° C, more preferably from about 24 to 30 ° C, even more preferably from about 25 to 29 ° C, even more preferably from about 26 to 28 ° C, and most preferably about 27 ° C. Preferably, baculovirus-induced characteristic changes were examined in Sf + cells after inoculation. Such examinations may include cell density dynamics and decreased viability during the post-infection period. It was found that a peak in viral titer is observed 3-5 days after infection, and a peak in the release of ORF2 from cells to the supernatant is obtained between 5 and 8 days, and / or when cell viability is reduced to less than 10%.

Thus, in one aspect, the present invention relates to an improved method for the preparation and / or isolation of a recombinant PCV2 ORF2 protein, preferably in the amounts described above, by i) allowing infection of a number of sensitive cells (see above) in culture with a recombinant viral vector with MOI, as defined above, ii) expressing PCV2 ORF2 protein through a recombinant viral vector, and iii) subsequently isolating PCV2 ORF2 from cell supernatant obtained between days 5 and 8 after infection, and / or when viable cell characteristics are reduced to less than 10%. Preferably, the recombinant viral vector is a recombinant baculovirus containing the PCV2 ORF2 DNA coding sequence, and the cells are Sf + cells. In addition, it is preferable to periodically examine in culture a macroscopic and microscopic manifestation of contamination, or atypical changes in cell morphology during the period after infection. Any culture with any signs of contamination should be discarded. Preferably, the expressed recombinant ORF2 protein is secreted by cells into the surrounding culture medium, which maintains cell viability. Then, ORF2 is isolated from the supernatant surrounding the cells, and not from the cells themselves.

The isolation process preferably begins by separating the cell debris from the ORF2 expressed in the medium through a separation step. Preferred separation steps include filtration, centrifugation at speeds up to about 20,000 x g, continuous centrifugation, chromatographic separation using ion exchange or gel filtration, and conventional immunoaffinity methods. These methods are known to those skilled in the art, for example, by (Harris and Angel (eds.), Protein purification methods - a practical approach, IRL press Oxford 1995). Most preferred separation methods include centrifugation at speeds up to about 20,000 x g and filtration. Preferred filtration methods include dead-end microfiltration and tangential (or cross-flow) filtration, including dead-end microfiltration on hollow fibers. Of this, dead-end microfiltration is preferred. The preferred pore size for dead-end microfiltration is between about 0.30-1.35 microns, more preferably between about 0.35-1.25 microns, even more preferably between about 0.40-1.10 microns, and most preferably between about 0.45-1.0 microns. It is believed that any conventional filtration membrane is suitable for the purposes of the present invention, and polyethersulfone membranes are preferred. During the filtration step, all low-mass nucleic acid molecules are removed.

Thus, in one additional aspect, the present invention relates to an improved method for the preparation and / or isolation of recombinant PCV2 ORF2 protein, preferably in the amounts described above, by i) allowing the infection of a number of sensitive cells (see above) in culture with a recombinant viral vector with MOI, as defined above, ii) expressing ORF2 PCV2 protein by a recombinant viral vector, iii) ORF2 PCV2 isolation from the supernatant of cells obtained between for days 5 and 8 after infection and / or when zhiz esposobnost cells is reduced to less than 10%, and iv) separating cell debris from the expressed ORF2 PCV2 by a separation step. Preferably, the recombinant viral vector is a baculovirus containing ORF2 DNA coding sequences, and the cells are SF + cells. Preferred centrifugation steps are as described above. Most preferred is dead-end microfiltration using a membrane with a pore size between about 0.30-1.35 microns, more preferably between about 0.35-1.25 microns, even more preferably between about 0.40-1.10 microns and most preferably between about 0.45-1.0 microns.

To isolate PCV2 ORF2, which will be used in an immunogenic or immunological composition, such as a vaccine, it is preferable to include an inactivation step to inactivate the viral vector. An “immunogenic or immunological composition” refers to a composition comprising at least one antigen that elicits an immunological response from a cellular and / or antibody-mediated immune response to a host composition or vaccine in question. Typically, an “immunological response” includes, but is not limited to, one or more of the following effects: production or activation of antibodies, B cells, helper T cells, suppressor T cells, and / or cytotoxic T cells and / or γδ T cells directed specifically against the antigen or antigens included in the subject composition or vaccine. Preferably, a therapeutic or protective immunological response is detected in the host, so that resistance to a new infection will be increased and / or the clinical severity of the disease will be reduced. Such protection can be demonstrated either by a decrease or by the absence of symptoms normally found for the infected host, fast recovery time and / or low viral titer in the infected host. Thus, the present invention also relates to a method for producing and / or isolating a recombinant PCV2 ORF2 protein, preferably in the amounts described above, by i) allowing the infection of a number of sensitive cells (see above) in culture by a recombinant viral vector with an MOI as defined above, ii) expression of ORF2 PCV2 protein by a recombinant viral vector, iii) ORF2 PCV2 isolation from the supernatant of cells obtained between for days 5 and 8 after infection and / or when cell viability decreases to less than h m 10%, iv) separating cell debris from the expressed ORF2 PCV2 via a separation step, and v) inactivating the recombinant viral vector.

Preferably, this inactivation is carried out immediately before or immediately after the filtration step, where the preferred time for inactivation is the time after the filtration step. For the purposes of the present invention, any conventional inactivation method can be used. So, inactivation can be carried out through chemical and / or physical influences. In preferred forms, the volume of the collected liquid is determined and the temperature is adjusted to approximately 32-42 ° C, more preferably approximately 34-40 ° C, and most preferably approximately 35-39 ° C. Preferred inactivation methods include the addition of cyclized binary ethyleneimine (BEI), preferably in a concentration of from about 1 to about 20 mM, preferably from about 2 to about 10 mM, even more preferably from about 2 to about 8 mM, even more preferably from about 3 to about 7 mM, most preferably about 5 mM. For example, inactivation involves adding a solution of 2-bromoethenamine hydrobromide, preferably about 0.4 M, cyclized to 0.2 M binary ethyleneimine (BEI) in 0.3 N NaOH, to liquids to a final concentration of about 5 mM BEI. Preferably, the liquids are then continuously stirred for 72-96 hours, and the inactivated collected liquids can be stored frozen at -40 ° C or lower, or between about 1-7 ° C. After completion of the inactivation, a sodium thiosulfate solution, preferably 1.0 M, is added to neutralize all residual BEI. Preferably, sodium thiosulfate is added in an equivalent amount compared to BEI previously added for inactivation. For example, if BEI is added to a final concentration of 5 mM, a 1.0 M sodium thiosulfate solution is added to a minimum final concentration of 5 mM to neutralize all residual BEI.

Thus, in one additional aspect, the present invention relates to a method for producing a recombinant PCV2 ORF2 protein, preferably in the amounts described above, by i) allowing the infection of a number of sensitive cells (see above) in culture with a recombinant viral vector with an MOI as defined above, ii) expression of ORF2 PCV2 protein by a recombinant viral vector, iii) ORF2 PCV2 isolation from the supernatant of cells obtained between 5 and day 8 after infection and / or when cell viability decreases Xia to less than 10%, iv) separating cell debris from the expressed ORF2 PCV2 by separation step and v) inactivating the recombinant viral vector. Preferably, the recombinant viral vector is a baculovirus containing ORF2 DNA coding sequences and the cells are SF + cells. Preferred separation methods are as described above, and a filtration step is most preferred. Preferred inactivation steps are those described above. Preferably, the inactivation is carried out between about 35-39 ° C. and in the presence of 2-8 mM BEI, even more preferably in the presence of about 5 mM BEI. Surprisingly, higher BEI concentrations adversely affected the PCV2 ORF2 protein.

In one additional aspect of the present invention, the method described above also includes a neutralization step after step v) . This step vi) involves the addition of an equivalent amount of a neutralizing inactivating substance in solution. Preferably, if the inactivating agent is BEI, it is preferable to add sodium thiosulfate to an equivalent amount. Thus, in a further aspect, step vi) comprises adding a sodium thiosulfate solution to a final concentration of from about 1 to about 20 mM, preferably from about 2 to about 10 mM, even more preferably from about 2 to about 8 mM, even more preferably, from about 3 to about 7 mM, most preferably about 5 mM, where the inactivating agent is BEI.

In preferred forms, and especially in forms using the recombinant ORF2 PCV2 protein in an immunogenic composition such as a vaccine, each batch of collected ORF2 will be tested for inactivation by passivation in the attachment-dependent, baculovirus-sensitive Sf + cells. In a preferred form of this test, 150 cm ^{2 of the} monolayer of the corresponding cell culture is inoculated with 1.0 ml of inactivated PCV2 fluids and maintained at 25-29 ° C. for 14 days with at least two passages. At the end of the maintenance period in the monolayers of cells, the cytopathogenetic effect (CPE) typical of baculovirus with ORF2 PCV2 is checked. Preferably, viruses are also used for positive control. Such controls may consist of a culture of Sf + cells inoculated with a non-inactivated control baculovirus with PCV2 ORF2 and one vial of Sf + cells left without inoculation. After incubation and passage, the absence of virus-infected cells for BEI-treated fluids with the virus will be a satisfactory inactivation test. Control cells inoculated with the control virus should have the CPE typical of baculovirus with ORF2 PCV2, and in a vial without inoculation, no signs of CPE of baculovirus with ORF2 PCV2 should be observed. Alternatively, at the end of the maintenance period, you can collect supernatant samples and inoculate in Sf + into a 96-well plate, which is filled with Sf + cells and then maintained at 25-29 ° C for 5-6 days. The plate is then fixed and stained with anti-ORF2 PCV2 antibody conjugated to FITC. The absence of CPE and ORF2 expression, as detected by IFA microscopy, for BEI-treated fluids with the virus is a satisfactory inactivation test. For control cells inoculated with the control virus, CPE and IFA activity should be observed, and a vial without inoculation should not show any signs of CPE baculovirus with ORF2 PCV2 and should not have activity in IFA.

Thus, an additional aspect of the present invention relates to an inactivation test to determine the inactivation efficiency of a recombinant viral vector, comprising the steps of: i) contacting at least a portion of the culture fluid containing the recombinant viral vector with an inactivating substance, preferably as described above, ii ) adding a neutralizing substance to neutralize the inactivating substance, preferably as described above, and iii) determining residual infectivity in the analyzes, as described above.

After inactivation, the relative amount of recombinant PCV2 ORF2 protein in a sample can be determined in a number of ways. Preferred methods for quantification include densitometry after SDS-PAGE, ELISA, and animal vaccination studies, which correlate known amounts of vaccine with clinical outcomes (serology, etc.). When using SDS-PAGE for quantification, a sample of material containing an unknown amount of recombinant PCV2 ORF2 protein is separated in a gel along with samples containing various known amounts of PCV2 ORF2 recombinant protein. A calibration curve can then be obtained from known samples, and the amount of recombinant PCV2 ORF2 in an unknown sample can be determined by comparison with this calibration curve. Because ELISA assays are generally accepted as an industry standard for quantifying antigen, they are preferred for quantification.

Thus, in an additional aspect, the present invention also relates to ELISA for the quantification of recombinant protein ORF2 PCV2. The preferred ELISA, as presented here, typically begins with a dilution of the antibody to capture 1: 6000 or to a suitable working dilution in the coating buffer. The preferred capture antibody is porcine anti-PCV2 PAb purified with protein G, and the preferred coating buffer is 0.05 M carbonate buffer, which can be prepared by combining 2.93 g of NaHCO ₃ (Sigma Cat No. S-6014, or equivalent) and 1 59 g of NaCO ₃ (Sigma Cat. No. S-6139, or equivalent). The mixture is combined with distilled water, or equivalent, to produce one liter at a pH of 9.6 ± 0.1. The capture antibody is then diluted 1: 6000, or to any other working dilution in coating buffer. For four tablets, for example, 42 ml of coating buffer and seven μl of antibody to capture are needed. Using the reverse pipetting method, 100 μl of diluted capture antibody was added to all wells. To get an even coating, gently tap on the sides of each tablet. The plates were then sealed with sealing films before stacking and the stack was covered with an empty 96-well plate. The plates were incubated overnight (14-24 hours) at 35-39 ° C. Then, each plate was washed three times with washing buffer using an ultra plus microtiter plate washing system at 250 μl / washing with three washes and without soaking time. After the last tablet wash, tap on a paper towel. Again, using the reverse pipetting method, 250 μl of blocking solution should be added to all wells. Test plates should be sealed and incubated for approximately one hour (± five minutes) at 35-37 ° C. Preferably, tablets are not stacked after this step. During the blocking stage, all test samples should be removed and thawed at room temperature. Then, four separate dilution plates should be prepared by adding 200 μl of the dilution solution to all remaining wells, except row A and row H, columns 1-3. Then six tubes should be labeled as follows, low titer, medium titer, high titer, inactivated / filtered (1: 240), inactivated / filtered (1: 480) and internal control. In the indicated tubes, appropriate dilutions should be prepared for the following test samples. Thawed prototypes should be mixed with shaking before use. For four tablets, the following dilutions should be performed: A) low titer should not be diluted: 3.0 ml with a low titer; B) negative control with a dilution of 1:30 (SF + cells): 3.77 ml of diluent + 130 μl of the negative control; C) an average titer with a dilution of 1:30 (8 μg / ml): 3.77 ml of diluent + 130 μl with an average titer; D) a high titer with a dilution of 1:90 (16 μg / ml): 2.967 ml of diluent + 33 μl with a high titer; E) inactivated / filtered with a dilution of 1: 240: 2.39 ml of diluent + 10 μl of inactivated / filtered sample; F) inactivated / filtered with a dilution of 1: 480: 1.0 ml of diluent + 1.0 ml of inactivated / filtered prepared sample (1: 240) from E above; G) internal control with a dilution of 1:30: 3.77 ml of diluent + 130 μl of internal control. Then 300 μl of prepared samples are added to the corresponding empty wells in dilution plates for plates 1-4. Then, a multichannel pipette was installed per 100 μl, the contents of row A were mixed by pipetting up and down at least 5 times, and then 100 μl was transferred to row B using the reverse pipetting method. The tips should be changed and the same procedure should be repeated on the plate to row G. The samples in these dilution plates are now ready for transfer to the test plates as soon as the test plates are washed 3 times with washing buffer using an ultra plus microtiter plate washing system (installation 250 μl / rinse, 3 rinses, without soaking time). After the last tablet wash, tap on a paper towel. The contents of the dilution plates are then transferred to a test plate using a simple transfer method. More specifically, starting from row H, 100 μl / well is transferred from the tablet (s) for dilution into the corresponding wells of the test tablet (s) using a reverse pipetting method. After each transfer, the pipette tips should be changed. From row G in the plate (s) for dilution, 100 μl / well is transferred to the corresponding wells of the test plate (s) using a reverse pipetting method. The same set of pipette tips can be used for the rest of the transfer. To ensure the homogeneity of the solution for transfer, the solution should be pipetted up and down at least 3 times before transfer. The test plate (s) are then sealed and incubated for 1.0 hour ± 5 minutes at 37 ° C ± 2.0 ° C. Again, it is preferable not to stack the tablets. The plates are then washed 3 times with washing buffer using an ultra plus microtiter plate washing system (250 μl / rinse setting, 3 washes, and without soaking time). After the last rinse with tablets, tap on a paper towel. Using the reverse pipetting method, 100 μl of antibody for detection diluted 1: 300, or in an appropriate working dilution, in a dilution solution is added to all wells of the test plate (s). For example, for four plates, 42 ml of dilution solution with 140 μl of capture antibody is required. The test plate (s) are then sealed and incubated for 1.0 hour ± 5 minutes at 37 ° C ± 2.0 ° C. The plates are then washed again 3 times with washing buffer using an ultra plus microtiter plate washing system (250 μl / rinse setting, 3 washes, and without soaking time). After the last wash with tablets, tap on a paper towel. The conjugate diluent is then prepared by adding 1% normal rabbit serum to the diluent. For four tablets, for example, 420 μl of normal rabbit serum is added to 42 ml of diluent. The conjugated antibody is diluted 1: 10000, or in any other suitable working dilution in a freshly prepared conjugate dilution solution for all wells of the test plate (s). Using the reverse pipetting method, 100 μl of this diluted antibody conjugate is added to all wells. Then the test plate (s) are sealed and incubated for 45 ± 5 minutes at 37 ° C ± 2.0 ° C. Preferably, the tablets are not stackable. The plates are then washed 3 times with washing buffer using a microtiter plate washing system (set to 250 μl / wash, 3 washes, and without soaking time). After the last rinse with tablets, tap on a paper towel. Then, immediately before use, equal volumes of TMB peroxidase substrate (reagent A) are mixed with peroxidase B solution (reagent B). The blended amount will vary depending on the number of tablets, but for each tablet 10 ml / tablet + 2 ml will be needed. Thus, for 4 tablets, this will be 21 ml of reagent A + 21 ml of reagent B. Using the reverse pipetting method, 100 μl of substrate is added to all wells of the test tablet (s). Then the plates are incubated at room temperature for 15 minutes ± 15 seconds. The reaction is stopped by adding 100 μl of 1 N HCl solution to all wells using the reverse pipetting method. Then, a spectrophotometer is turned on to read the plates after ELISA and allow it to pass through the usual phases of diagnosis and testing in a conventional manner.

In an additional aspect, the invention relates to a method for constructing a recombinant viral vector containing PCV2 ORF2 DNA and expressing large quantities of PCV2 ORF2 protein in susceptible cell infections. Surprisingly, the recombinant viral vector provided herein expresses large amounts, as defined above, of PCV2 ORF2 after susceptible cell infection. Thus, the present invention also relates to an improved method for the preparation and / or isolation of PCV2 ORF2 protein, preferably comprising the step of: constructing a recombinant viral vector containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein. Preferably, the viral vector is a recombinant baculovirus. The details of the method for constructing recombinant viral vectors containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein as described herein are described in the following: in preferred forms, a recombinant viral vector containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein used for cell infection is obtained by transfection a transfer vector having the ORF2 gene cloned therein into a viral vector. Preferably, only part of the transfer vector containing ORF2 DNA is transfected into the viral vector. The term "transfection into a viral vector" means and is used as a synonym for "insert" or "clone" heterologous DNA into a viral vector, such as a baculovirus vector. The viral vector is preferably, but not necessarily, a baculovirus.

Thus, according to a further aspect of the present invention, a recombinant viral vector is prepared by recombination between a transfer vector containing heterologous PCV2 ORF2 DNA and a viral vector, preferably a baculovirus, even more preferably a linearized replication-defective baculovirus (such as Baculo Gold DNA). "Vector transfer" means a DNA molecule containing at least one point of origin of replication, a heterologous gene, in the present case, ORF2 PCV2, and DNA sequences that allow you to clone the specified heterologous gene into a viral vector. Preferably, sequences allowing the cloning of a heterologous gene into a viral vector flank the heterologous gene. Even more preferably, these sequences are at least partially homologous to the sequences of the viral vector. The sequence homology then allows the recombination of both molecules, the viral vector and the carrier vector, to produce a recombinant viral vector containing a heterologous gene. One preferred transfer vector is the pVL1392 vector (BD Biosciences Pharmingen), designed for cotransfection with BaculoGold DNA into a preferred Sf + cell line. Preferably, said carrier vector comprises PCV2 ORF2 DNA. The cotransfection construct is approximately 10387 base pairs in length.

In more preferred forms, the methods of the present invention begin by isolating PCV2 ORF2 DNA. This can generally be done from a known or unknown strain, since ORF2 DNA appears to be highly conserved with at least about 95% sequence identity between different isolates. Any PCV2 ORF2 gene known in the art can be used for the purposes of the present invention, as each will be expressed as a supernatant. PCV ORF2 DNA is preferably amplified using PCR methods, even more preferably, together with the introduction of the Kozak 5'-flanking consensus sequence (CCGCCAUG) (SEQ ID NO 1) and / or EcoR1 3'-flanking region (GAATTC) (SEQ ID NO 2 ) By introducing the Kozak 5'-consensus, the natural AUG start codon from ORF2 PCV2 is preferably removed. The 3'-section of EcoR1 is preferably introduced below the stop codon of ORF2 PCV2. More preferably, it is introduced below the poly A transcription termination A sequence, which itself is located below the PCV2 stop codon ORF2. The use of the Kozak consensus sequence, in particular as described above, was found to increase the expression level of the subsequent PCV2 ORF2 protein. Amplified PCV2 ORF2 DNA with these additional sequences is cloned into a vector. A preferred vector for this initial cloning step is the pGEM-T-Easy vector (Promega, Madison, WI). PCV2 ORF2 DNA, including some sequences of the pGEM vector (SEQ ID NO: 7), is preferably cut from the vector at the Not1 restriction site. The resulting DNA is then cloned into a transfer vector.

Thus, in one aspect, the present invention relates to a method for constructing a recombinant viral vector containing PCV2 ORF2 DNA. This method includes the steps of: i) cloning recombinant PCV2 ORF2 into a carrier vector; and ii) transferring a portion of the transfer vector containing recombinant PCV2 ORF2 to the viral vector to obtain a recombinant viral vector. Preferably, the vector is a vector described above, or constructed as described above or as an example shown in figure 1. Thus, in a further aspect, the vector used for constructing a recombinant viral vector, as described here, contains the sequence of SEQ ID NO: 7.

In an additional aspect, the method further includes, before step i) the following step: in vitro amplification of the PCV2 ORF2 DNA, where the flanking PCV2 ORF2 DNA sequences are modified as described above. Methods for DNA amplification ORF2 PCV2 and modifications flanking posledovatelnostey in vitro, cloning in vitro amplified DNA ORF2 PCV2 into a transfer vector and suitable transfer vectors are described above, as an example shown in Figure 1, or known to those skilled in the art. Thus, in an additional aspect, the present invention relates to a method for constructing a recombinant viral vector containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein, comprising the steps of: i) in vitro amplification of PCV2 ORF2 DNA, where the flanking sequences of said PCF2 ORF2 DNA are modified, ii ) cloning amplified PCV2 ORF2 DNA into a carrier vector; and iii) transfecting the vector of the vector or part thereof containing recombinant PCV2 ORF2 DNA into a viral vector to obtain a recombinant viral vector. Preferably, the modification of the flanking DNA sequences of ORF2 PCV2 is carried out as described above, for example, by introducing the Kozak 5 ′ sequence and / or the EcoR1 region, preferably as described above.

In an additional aspect, a method for producing and / or isolating a recombinant protein expressed from an open reading frame of 2 PCV2 is provided. The method typically includes the steps of: i) cloning recombinant PCV2 ORF2 into a carrier vector; ii) transfecting a portion of the carrier vector containing recombinant PCV2 ORF2 into a virus; iii) infection of cells in the medium with a transfected virus; iv) allowing expression of the recombinant protein with ORF2 PCV2 recombinant virus; v) separating cells from the supernatant; and vi) isolating the expressed PCV2 ORF2 protein from the supernatant.

Methods for cloning recombinant PCV2 ORF2 DNA into a transfer vector are described above. Preferably, the transfer vector comprises the sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7. However, the transfer vector may contain any PCV2 ORF2 DNA, unmodified or modified, provided that the PCV2 ORF2 DNA is expressed in cell culture upon transfection into a recombinant viral vector. Preferably, the recombinant viral vector contains the sequence of SEQ ID NO: 8. Moreover, methods for infection of cells, preferably infection of insect cells, by a certain number of recombinant baculoviruses containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein are described in detail above. Moreover, the steps of separating cells from the supernatant, as well as the steps of isolating the expressed PCV2 ORF2 protein, are also described in detail above. Any of these specific steps of the method, as described herein, are part of the method for producing and / or isolating a recombinant protein expressed from an open reading frame 2 from PCV2, as described above. Preferably, the cells are SF + cells. Even more preferably, cell cultures have a cell number between about 0.3-2.0 × 10 ⁶ cells / ml, more preferably between about 0.35-1.9 × 10 ⁶ cells / ml, even more preferably between about 0 4-1.8 × 10 ⁶ cells / ml, even more preferably between about 0.45-1.7 × 10 ⁶ cells / ml, and most preferably between about 0.5-1.5 × 10 ⁶ cells / ml Preferably, the recombinant viral vector containing PCV2 ORF2 DNA has a preferred infection multiplicity (MOI) between about 0.03-1.5, more preferably between about 0.05-1.3, even more preferably between about 0.09 -1.1, even more preferably, between about 0.1-1.0, and most preferably, about 0.5, when sensitive cells are used for infection. It is preferable to isolate the PCV2 ORF2 protein from the cell supernatant obtained between days 5 and 8 after infection and / or by reducing cell viability to less than 10%. Preferably, to obtain the PCV2 ORF2 protein, cells are cultured at 25-29 ° C. Preferably, the separation step is a centrifugation step or a filtration step.

Optionally, the method may include the step of amplifying the PCV2 ORF2 DNA from the PCV2 strain before cloning the PCV2 ORF2 DNA into the transfer vector. In preferred forms, the Kozak 5'-sequence, the 3'-section of EcoR1, and combinations thereof may also be added to the amplified sequence, preferably before or during amplification. Kozak's preferred 5'-sequence contains SEQ ID NO: 1. Preferred EcoR1 3'-region contains SEQ ID NO: 2. Preferred PCV2 ORF2 DNA contains the nucleotide sequence with Genbank Accession Number AF086834 (SEQ ID NO: 3) and SEQ ID NO: 3 : 4. Preferred recombinant protein ORF2 PCV2 contains the amino acid sequence of SEQ ID NO: 5, which is a protein encoded by SEQ ID NO: 3 (Genbank Accession No. AF086834) and SEQ ID No: 6, which is a protein encoded by SEQ ID NO: 4. The preferred medium contains serum-free medium for insect cells, still more preferably medium Excell 420. When an optional amplification step is carried out, it is preferable to first clone the amplified open reading frame 2 into a first vector, cut open reading frame 2 from the first vector, and use the excised open reading frame for cloning into the transfer vector. The preferred cell line for cotransfection is the SF + cell line. The preferred cotransfection virus is baculovirus. In a preferred form of this method, the transfected portion of the carrier vector contains SEQ ID NO: 8. Finally, for this method, it is preferable to isolate the protein from the open reading frame 2 (ORF2) of PCV2 from the cell culture supernatant at least 5 days after cell infection with the virus .

Thus, in a further aspect, the invention relates to a method for producing and / or isolating an open reading frame of 2 PCV2, comprising the steps of: i) amplifying PCV2 ORF2 DNA in vitro , preferably by adding a Kozak 5 ′ sequence and / or adding 3 ′ - restriction site EcoR1, ii) cloning of amplified ORF2 PCV2 into a carrier vector; iii) transfecting a portion of the carrier vector containing recombinant PCV2 ORF2 into the virus; iv) cell infections in the medium with a transfected virus; v) the expression of a transfected virus recombinant protein with ORF2 PCV2; vi) separating cells from the supernatant; and vii) isolating the expressed PCV2 ORF2 protein from the supernatant.

In an additional aspect, the present invention relates to a method for producing a composition comprising a PCV2 ORF2 protein and an inactivated viral vector. The method includes the steps of: i) cloning the amplified ORF2 PCV2 into a carrier vector; ii) transfecting a portion of the carrier vector containing recombinant PCV2 ORF2 into a virus; iii) infection of cells in the medium with a transfected viral vector; iv) expression of a recombinant protein transfected virus with PCV2 ORF2; v) separating cells from the supernatant; vi) isolating the expressed PCV2 ORF2 protein from the supernatant; and vii) inactivating the recombinant viral vector. Preferably, the recombinant viral vector is a baculovirus containing ORF2 DNA coding sequences, and the cells are SF + cells. Preferred separation steps are the steps described above, where the filtration step is most preferred. Preferred inactivation steps are those described above. Preferably, the inactivation is carried out between about 35-39 ° C. and in the presence of 2-8 mM BEI, even more preferably in the presence of about 5 mM BEI. Surprisingly, higher BEI concentrations negatively affect the PCV2 ORF2 protein, and lower concentrations are ineffective for inactivating the viral vector within 24-72 hours of inactivation. Preferably, the inactivation is carried out for at least 24 hours, even more preferably from 24 to 72 hours.

In a further aspect, a method for preparing a composition comprising an PCV2 ORF2 protein and an inactivated viral vector, as described above, also includes a neutralization step after step vii) . This step viii) involves the addition of an equivalent amount of a neutralizing inactivating substance in solution. Preferably, if the inactivating agent is BEI, it is preferable to add sodium thiosulfate to an equivalent amount. Thus, in a further aspect, step viii) comprises adding a sodium thiosulfate solution to a final concentration of from about 1 to about 20 mM, preferably from about 2 to about 10 mM, even more preferably from about 2 to about 8 mM, even more preferably, from about 3 to about 7 mM, most preferably about 5 mM, where the inactivating agent is BEI.

In a further aspect, a method of preparing a composition comprising an PCV2 ORF2 protein and an inactivated viral vector as described above includes, before step i) the following step: in vitro amplification of PCV2 ORF2 DNA, where the flanking PCV2 ORF2 DNA sequences are modified as described above. Methods for DNA amplification ORF2 PCV2 and modifications flanking posledovatelnostey in vitro, cloning in vitro amplified DNA ORF2 PCV2 into a transfer vector and suitable transfer vectors are described above, as an example shown in Figure 1, or known to those skilled in the art. Thus, in a further aspect, the method comprises the steps of: i) amplifying an ORF2 PCV2 DNA in vitro , where the flanking sequences of said ORF2 PCV2 DNA are modified, ii) cloning the amplified PCF ORF2 DNA into a transfer vector; and iii) transfecting the vector of the vector or part thereof containing recombinant PCV2 ORF2 DNA into a viral vector to obtain a recombinant viral vector; iv) infection of cells in the medium with a transfected virus; v) expression of a recombinant PCV2 ORF2 protein by a transfected virus; vi) separating cells from the supernatant; vii) isolating the expressed PCV2 ORF2 protein from the supernatant; viii) inactivating the recombinant viral vector, preferably in the presence of from about 1 to about 20 mM BEI, most preferably in the presence of about 5 mM BEI; and ix) adding an equivalent amount of an inactivating agent neutralizing agent in solution, preferably adding a sodium thiosulfate solution to a final concentration of from about 1 to about 20 mM, preferably about 5 mM, if the inactivating agent is BEI.

In another aspect, the present invention relates to a method for preparing a composition, preferably an antigenic composition, for example, such as a vaccine, to elicit an immune response against PCV2. Typically, this method includes the steps of transfecting the construct into a virus, where the construct contains i) recombinant DNA from ORF2 PCV2, ii) infection of cells in the culture medium with transfected virus, iii) expression of the recombinant protein ORF2 PCV2 by virus, iv) isolation of the expressed protein ORF2 from the supernatant, v) and preparing the composition by combining the isolated protein with a suitable adjuvant and / or other pharmaceutically acceptable carrier.

“Adjuvants” as used herein may include aluminum hydroxide and aluminum phosphate, saponins, for example, Quil A, QS-21 (Cambridge Biotech Inc., Cambridge MA), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, AL), water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion. The emulsion may be based, in particular, on light liquid liquid paraffin (European Pharmacopoeia standard); isoprenoid oil such as squalane or squalene; oil obtained after oligomerization of alkenes, in particular isobutene or decene; esters of acids or alcohols containing a linear alkyl group, more particularly vegetable oils, ethyl oleate, propylene glycol di- (caprylate / caprate), glyceryl tri- (caprylate / caprate) or propylene glycol dioleate; branched fatty acid esters or alcohols, in particular isostearic acid esters. To obtain an emulsion, oil is used in combination with emulsifiers. Emulsifiers are preferably non-ionic surfactants, in particular esters of sorbitan, mannide (for example, anhydromannite oleate), glycol, polyglycerol, propylene glycol and butyric, isostearic, ricinoleic or hydroxystearic acid, which are, optionally, ethoxylated polypropylene and block copolymers polyoxyethylene, in particular pluronic products, especially L121. See Hunter et al., The Theory and Practical Application of Adjuvants (Ed. Stewart-Tull, D. E. S.). John Wiley and Sons, NY, pp51-94 (1995) and Todd et al., Vaccine 15: 564-570 (1997).

For example, the SPT emulsion described on page 147 of "Vaccine Design, The Subunit and Adjuvant Approach" edited by M. Powell and M. Newman, Plenum Press, 1995, and the MF59 emulsion described on page 183 of the same book can be used.

A further example of an adjuvant is a compound selected from polymers of acrylic or methacrylic acid and copolymers of maleic anhydride and an alkenyl derivative. Preferred adjuvant compounds are polymers of acrylic or methacrylic acid, which are cross-linked, especially with esters of polyalkenyl with sugars or polyalcohols. These compounds are known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Specialists in this field can also refer to US patent No. 2909462, which discloses such acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, where the hydrogen atoms of at least three hydroxyls are replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. Preferred radicals are those containing from 2 to 4 carbon atoms, for example, vinyls, allyls and other ethylenically unsaturated groups. Unsaturated radicals themselves may contain other substituents, such as methyl. Particularly suitable are products sold under the name carbopol; (BF Goodrich, Ohio, USA). They are cross-linked with allyl sucrose or with allyl pentaerythritol. Among them, carbopol 974P, 934P and 971P can be mentioned. Most preferred is the use of carbopol 971P. Among the copolymers of maleic anhydride and an alkenyl derivative are copolymers of EMA (Monsanto), which are copolymers of maleic anhydride and ethylene. By dissolving these polymers in water, an acidic solution is obtained, which is neutralized, preferably to physiological pH, to obtain an adjuvant solution into which the immunogenic, immunological or vaccine composition itself can be administered.

Additional suitable adjuvants include but are not limited to, among many others, the RIBI adjuvant system (Ribi Inc.), block copolymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), monophosphoryl lipid A, lipid amine adjuvant avridin, a thermolabile enterotoxin from E. coli (recombinant or other), cholera exotoxin, IMS 1314 or muramyl dipeptide.

Preferably, the adjuvant is added in an amount of from about 100 μg to about 10 mg per dose. Even more preferably, the adjuvant is added in an amount of from about 100 μg to about 10 mg per dose. Even more preferably, the adjuvant is added in an amount of from about 500 μg to about 5 mg per dose. Even more preferably, the adjuvant is added in an amount of from about 750 μg to about 2.5 mg per dose. Most preferably, the adjuvant is added in an amount of about 1 mg per dose.

Thus, in a further aspect, a method for producing an antigenic composition, such as a vaccine, for eliciting an immune response against PCV2, includes i) preparing and isolating the PCV2 ORF2 protein, and ii) mixing it with a suitable adjuvant. Preferably, the adjuvant is carbopol 971P. Even more preferably, carbopol 971 P is added in an amount of from about 500 μg to about 5 mg per dose, even more preferably in an amount of from about 750 μg to about 2.5 mg per dose, and most preferably, in an amount of about 1 mg per dose . Preferably, process step i) includes a process step as described for the preparation and isolation of PCV2 ORF2. For example, in preferred forms of this method, a construct containing PCV2 ORF2 DNA is prepared in a carrier vector. Suitable carrier vectors and methods for their preparation are described above. Optionally, the method may include in the step of amplifying ORF2 from the PCV2 strain by PCR before cloning the ORF2 into a transfer vector. Preferred open reading frames for the sequence, Kozak sequence, EcoR1 3'-region sequence, recombinant protein sequence, transfected construct sequences, medium, cells and viruses are as described in the previous methods. Another optional step of this method involves cloning the amplified PCV2 ORF2 DNA into a first vector, cutting out the ORF2 DNA from the first vector, and using the cut PCV2 ORP2 DNA for cloning in the transfer vector. As with other methods, it is preferable to wait at least 5 days after infection of the cells with transfected baculovirus before isolation of the recombinant ORF2 protein from the supernatant. Preferably, the isolation step of the method also includes the step of separating the medium from the cells and cell debris. This can be done in many ways, however, for simplicity and convenience, it is preferable to filter the cells, cell debris and culture medium through a filter with a pore size in the range from about 0.45 microns to about 1.0 microns. Finally, for this method, it is preferable to include the stage of inactivation of the virus before combining the selected recombinant protein ORF2 PCV2 in the composition. This can be accomplished in a variety of ways, however, in the practice of the present invention, BEI is preferred.

Thus, in a further aspect, the method comprises the steps of: i) amplifying an ORF2 PCV2 DNA in vitro , where the flanking sequences of said ORF2 PCV2 DNA are modified, ii) cloning the amplified PCF ORF2 DNA into a transfer vector; and iii) transfecting the vector of the vector or part thereof containing recombinant PCV2 ORF2 DNA into a viral vector to obtain a recombinant viral vector; iv) infection of cells in the medium with a transfected vector; v) expression of a recombinant protein with ORF2 PCV2 transfected virus; vi) separating cells from the supernatant; vii) isolating the expressed PCV2 ORF2 protein from the supernatant; viii) inactivating the recombinant viral vector, preferably in the presence of from about 1 to about 20 mM BEI, most preferably in the presence of about 5 mM BEI; ix) adding an equivalent amount of an inactivating substance neutralizing agent in solution, preferably adding a sodium thiosulfate solution to a final concentration of from about 1 to about 20 mM, preferably about 5 mM, if the inactivating substance is BEI, and x) adding a suitable amount of adjuvant, preferably, the addition of carbopol, more preferably carbopol 971P, even more preferably in amounts as described above (for example, from about 500 μg to p about 5 mg per dose, even more preferably in an amount of from about 750 μg to about 2.5 mg per dose, and most preferably in an amount of about 1 mg per dose).

In addition, the composition may include one or more pharmaceutical acceptable carriers. As used herein, a “pharmaceutical acceptable carrier” includes, without exception, all solvents, dispersants, coatings, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents that delay absorption of the drug, and the like. Most preferably, the composition provided herein contains PCV2 ORF2 protein isolated from a supernatant of in vitro cultured cells, wherein said cells are infected with a recombinant viral vector containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein, and wherein said cell culture is treated from about 2 to about 8 mM BEI, preferably about 5 mM BEI to inactivate the viral vector, and an equivalent concentration of neutralizing agent, preferably sodium thiosulfate solution to a final concentrations from about 2 to about 8 mM, preferably about 5 mM, carbopol, more preferably 971P carbopol, preferably in amounts from about 500 μg to about 5 mg per dose, even more preferably in amounts from about 750 μg to about 2 5 mg per dose, and most preferably, in an amount of about 1 mg per dose, and with saline, preferably in an amount of from about 50 to about 90% (v / v), more preferably, about m waiting 60-80% (vol. / vol.), still more preferably about 70% (vol. / vol.).

Thus, an additional aspect relates to a method for producing an antigenic composition, for example, such as a vaccine, to elicit an anti-PCV2 immune response comprising the steps of: i) amplifying PCV2 ORF2 DNA in vitro , where the flanking sequences of said PCV2 ORF2 DNA are modified, ii) cloning amplified PCV2 ORF2 DNA into a transfer vector; and iii) transfecting the vector of the vector or part thereof containing recombinant PCV2 ORF2 DNA into a viral vector to obtain a recombinant viral vector; iv) infection of cells in the medium with a transfected virus; v) expression of the recombinant protein with ORF2 PCV2 transfected virus; vi) separating cells from the supernatant; vii) isolating the expressed PCV2 ORF2 protein from the supernatant; viii) inactivating the recombinant viral vector, preferably in the presence of from about 1 to about 20 mM BEI, most preferably in the presence of about 5 mM BEI; ix) adding an equivalent amount of an inactivating substance neutralizing agent in solution, preferably adding a sodium thiosulfate solution to a final concentration of from about 1 to about 20 mM, preferably about 5 mM, if the inactivating substance is BEI, x) adding a suitable amount of adjuvants, preferably adding carbopol, more preferably carbopol 971P, even more preferably in amounts as described above (for example, from about 500 μg to pr about 5 mg per dose, even more preferably, in an amount of from about 750 μg to about 2.5 mg per dose, and most preferably, in an amount of about 1 mg per dose); and xi) adding saline, preferably in an amount of from about 50 to about 90% (v / v), more preferably between about 60-80% (v / v), even more preferably, about 70% (v / v). Optionally, this method may also include the addition of a stabilizer. The stabilizer, as used here, refers to an antimicrobial active agent, for example, such as gentamicin, merthiolate, etc. In particular, the addition of a stabilizer is most preferred for the preparation of a multi-dose composition. These antimicrobial active agents are added in concentrations effective to prevent any microbiological contamination of the composition of interest or to inhibit any microbiological growth in the composition of interest.

Moreover, this method may also include the addition of any stabilizer, for example, such as saccharides, trehalose, mannitol, sucrose and the like, to increase and / or maintain shelf life. However, it was unexpectedly discovered that the resulting composition was immunologically effective for a period of at least 24 months without the addition of any additional stabilizer.

In an additional aspect, the present invention relates to products obtained by the methods described above. In particular, the present invention relates to a composition comprising a recombinantly expressed PCV2 ORF2 protein. Moreover, the present invention also relates to a composition comprising a recombinantly expressed PCV2 protein ORF2 protein isolated from an insect cell culture supernatant. Moreover, the present invention also relates to a composition comprising a recombinantly expressed PCV2 protein ORF2 protein isolated from an insect cell culture supernatant. Preferably, this composition also contains a means for inactivating viral vectors. Preferably, said inactivation agent is BEI. Moreover, the present invention also relates to a composition comprising a recombinantly expressed PCV2 protein ORF2 protein isolated from the supernatant of an insect cell culture and comprising an agent suitable for inactivating viral vectors, preferably BEI and a neutralizing agent to neutralize the inactivating agent. Preferably, this neutralizing agent is sodium thiosulfate using BEI as an inactivating agent.

In another aspect, the present invention relates to an immunogenic composition that elicits an immune response and, more preferably, provides protective immunity against clinical signs of PCV2 infection. A composition typically comprises a polypeptide or fragment thereof expressed from an open reading frame 2 (ORF2) from PCV2 as an antigenic component of the composition.

PCV2 DNA and ORF2 protein, as used here to prepare the composition, as well as used in the methods provided herein, is a highly conserved domain in PCV2 isolates and, as a result, any PCV2 ORF2 will be effective as a source of DNA and / or PCV ORF2 polypeptide, as used here. A preferred ORV2 protein of PCV2 is the protein of SEQ ID NO. 11. A preferred PCV ORF2 polypeptide is provided herein as SEQ ID NO. 5, however, it will be understood by those skilled in the art that this sequence can vary as much as 6-10% of the sequence homology and still maintain antigenic characteristics that make it applicable in the immunogenic composition. The antigenic characteristics of the immunological composition can, for example, be determined by an infection experiment, as described in Example 4. Moreover, the antigenic characteristics of the modified antigen are still preserved when the modified antigen provides at least 70%, preferably 80%, more preferably 90% of the protective immunity compared to the PCV2 ORF2 protein encoded by the polynucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 4. An “immunogenic composition”, as used herein, means an PCV2 ORF2 protein that elicits a “immunological response” from a cellular and / or antibody-mediated immune response to PCV2 ORF2 protein from a host. Preferably, the immunogenic composition is capable of providing protective immunity against PCV2 infection and related clinical signs. In some forms, the immunogenic portions of the PCV2 ORF2 protein are used as the antigenic component of the composition. The term “immunogenic portion”, as used herein, refers to truncated and / or substituted forms or fragments of the PCV2 ORF2 protein and / or polynucleotide, respectively. Preferably, such truncated and / or substituted forms or fragments contain at least 6 continuous amino acids from the full length ORF2 polypeptide. More preferably, truncated or substituted forms or fragments will have at least 10, more preferably at least 15, and even more preferably at least 19 continuous amino acids from the full length ORF2 polypeptide. Two preferred sequences in this regard are presented here as SEQ ID NO. 9 and 10. In addition, it is understood that such sequences may form part of larger fragments or truncated forms. The additional preferred ORV2 PCV2 polypeptide provided herein encodes the nucleotide sequences of SEQ ID NO: 3 or SEQ ID NO: 4. However, it will be understood by those skilled in the art that this sequence may vary as much as by 6-20% sequence homology, and maintain antigenic characteristics applicable in the immunogenic composition. In some forms, a truncated or substituted form or ORF2 fragment is used as an antigenic component of the composition. Preferably, such truncated or substituted forms or fragments will contain at least 18 continuous nucleotides from the full-length nucleotide sequence of ORF2, for example, SEQ ID NO: 3 or SEQ ID NO: 4. More preferably, truncated or substituted forms or fragments will have at least 30, more preferably at least 45, and even more preferably at least 57 continuous nucleotides of the full-length nucleotide sequence of ORF2, for example, SEQ ID NO: 3 or SEQ ID NO: 4.

"Sequence identity", as is known in the art, refers to the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, namely, a control sequence and a given sequence to be compared with a control sequence. Sequence identity is determined by comparing this sequence with a control sequence after optimal sequence alignment to obtain the highest degree of sequence similarity, as determined by matching between strands of such sequences. With this alignment, sequence identity is established based on position after position, for example, sequences are “identical” at a particular position if nucleotides or amino acid residues are identical at that position. Then, the total number of such identical positions is divided by the total number of nucleotides or residues in the control sequence to obtain% sequence identity. Sequence identity can be easily calculated by known methods, including, but not limited to, methods described in Computational Molecular Biology, Lesk, AN, ed., Oxford University Press, New York (1988), Biocomputing: Informatics and Genome Projects, Smith, DW , ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988), the contents of which are incorporated herein by reference. Preferred methods for determining sequence identity are designed to provide the best match between the sequences tested. Methods for determining sequence identity are encoded in publicly available computer programs defining sequence identity between these sequences. Examples of such programs include, but are not limited to, the GCG software package (Devereux, J., et al., Nucleic acids Research, 12 (1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, SF et al. J. Molec. Biol. 215: 403-410 (1990)). The BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, MD 20894, Altschul, SF et al., J. Molec. Biol., 215: 403-410 ( 1990), the contents of which are incorporated herein by reference). These programs optimally align sequences using the default skipping weights to obtain the highest level of sequence identity between this and the control sequence. By way of illustration, a polynucleotide with a nucleotide sequence having, for example, at least 85%, preferably 90%, even more preferably 95% “sequence identity” with the control nucleotide sequence, is understood to mean that the nucleotide sequence of this polynucleotide is identical with a control sequence, except that the sequence of a given polynucleotide may contain up to 15, preferably up to 10, even more preferably int Lot of up to 5 point mutations for every 100 nucleotides of the control nucleotide sequence. In other words, in a polynucleotide with a nucleotide sequence having at least 85%, preferably 90%, even more preferably 95% identity with respect to the control nucleotide sequence, up to 15%, preferably 10%, even more preferably 5% nucleotides in the control sequence can be deleted or replaced with other nucleotides, or the number of nucleotides up to 15%, preferably 10%, even more preferably 5% of all nucleotides in the control sequence can be inserted the control sequence. These mutations in the control sequence can be present at the 5'- or 3'-terminal positions of the control nucleotide sequence, or anywhere between these end positions, distributed either individually among the nucleotides in the control sequence, or in one or more continuous groups in the control sequence . Similarly, a polypeptide with a given amino acid sequence having at least, for example, 85%, preferably 90%, even more preferably 95% sequence identity with a control amino acid sequence, means that this amino acid sequence of the polypeptide is identical to the control sequence, for except that a given polypeptide sequence may contain up to 15, preferably up to 10, even more preferably up to 5 amino acids slot substitutions for every 100 amino acids of the control amino acid sequence. In other words, to obtain a given polypeptide sequence having at least 85%, preferably 90%, even more preferably 95% sequence identity with a control amino acid sequence, up to 15%, preferably up to 10%, even more preferably up to 5% of amino acid residues in the control sequence can be deleted or replaced with other amino acids, or the number of amino acids, up to 15%, preferably up to 10%, even more preferably up to 5 % of the total number of amino acid residues in the control sequence can be inserted into the control sequence. These changes in the control sequence may be present at the N- or C-terminal positions of the control amino acid sequence or anywhere between these terminal positions, distributed either individually among the residues in the control sequence, or in one or more continuous groups in the control sequence. Preferably, the positions of residues that are not identical differ by conservative amino acid substitutions. However, conservative substitutions are not included in the matches when determining sequence identity.

“Sequence homology”, as used herein, refers to a method for determining the affinity of two sequences. To determine sequence homology, two or more sequences are optimally aligned, and gaps are added if necessary. However, unlike “sequence identity,” conservative amino acid substitutions are considered coincidences in determining sequence homology. In other words, to obtain a polypeptide or polynucleotide having 95% sequence homology with a control sequence, 85%, preferably 90%, even more preferably 95% of the amino acid residues or nucleotides in the control sequence must coincide with another amino acid or nucleotide or contain conservative substitutions, or the number of amino acids or nucleotides up to 15%, preferably up to 10%, even more preferably up to 5% of the total number of amino acid residues or nucleotides the reference sequence, not including conservative substitutions, can be inserted into the control sequence. Preferably, the homologous sequence comprises at least a length of 50, even more preferably 100, even more preferably 250, even more preferably 500 nucleotides.

“Conservative substitution” means the replacement of an amino acid residue or nucleotide with another amino acid residue or nucleotide having similar characteristics or properties, including size, hydrophobicity, etc., so that the overall functionality does not change significantly.

“Highlighted” means altered by the “human hand” compared to the natural state, that is, if it exists in nature, it has been changed, or removed from its natural environment, or both. For example, a polynucleotide or polypeptide naturally present in a living organism is not "isolated", however, the same polynucleotide or polypeptide separated from substances coexisting with it in its natural state is "isolated", as the term is used here.

Thus, in an additional aspect, the present invention relates to an immunogenic composition effective to reduce the severity of clinical symptoms associated with a PCV2 infection containing the PCV2 ORF2 protein. Preferably, the PCV2 ORF2 protein is one of the proteins described above. Preferably, said PCV2 ORF2 protein is

i) a polypeptide containing the sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11;

ii) any polypeptide that is at least 80% homologous to the polypeptide of i);

iii) any immunogenic portion of the polypeptides from i) and / or ii);

iv) the immunogenic part of iii) containing at least 10 contiguous amino acids in the sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11;

v) a polypeptide encoded by a DNA containing the sequence of SEQ ID NO: 3 or SEQ ID NO: 4;

vi) any polypeptide encoded by the polynucleotide is at least 80% homologous to the polynucleotide from v);

vii) any immunogenic portion of the polypeptides encoded by the polynucleotide of v) and / or vi);

viii) the immunogenic part of vii), where the polynucleotide encoding the specified immunogenic part contains at least 30 contiguous nucleotides in the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

Preferably, any of these immunogenic parts possesses the immunogenic characteristics of the PCV2 ORF2 protein encoded by the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

In a further aspect, the PCV2 ORF2 protein is provided in an immunological composition at an antigen level effective to induce a desired immune response, namely, to reduce the incidence or severity of clinical signs caused by PCV2 infection. Preferably, the PCV2 ORF2 protein content is at least 0.2 μg antigen / ml of the final immunogenic composition (μg / ml), more preferably from about 0.2 to about 400 μg / ml, even more preferably from about 0.3 up to about 200 μg / ml, even more preferably from about 0.35 to about 100 μg / ml, even more preferably from about 0.4 to about 50 μg / ml, even more preferably from about 0.45 to about 30 μg / ml, even more preferably from about 0.6 to about 15 μg / ml, even more preferably from about 0.75 to about 8 μg / ml, even more preferably from about 1.0 to about 6 μg / ml, even more preferably from about 1 3 to about 3.0 μg / ml, even more preferably from about 1.4 to about 2.5 μg / ml, even more preferably from about 1.5 to about 2.0 μg / ml, and most preferably approximately 1.6 μg / ml.

In an additional aspect, the level of ORF2 antigen is at least 0.2 μg of PCV2 ORF2 protein, as described above, per dose of the final antigenic composition (μg / dose), more preferably from about 0.2 to about 400 μg / dose, still more preferably, from about 0.3 to about 200 μg / dose, even more preferably from about 0.35 to about 100 μg / dose, even more preferably from about 0.4 to about 50 μg / dose, even more preferably from about 0.45 to about 3 0 μg / dose, even more preferably from about 0.6 to about 15 μg / dose, even more preferably from about 0.75 to about 8 μg / dose, even more preferably from about 1.0 to about 6 μg / a dose, even more preferably, from about 1.3 to about 3.0 μg / dose, even more preferably, from about 1.4 to about 2.5 μg / dose, even more preferably, from about 1.5 to about 2 , 0 μg / dose, and most preferably, about 1.6 μg / dose.

The PCV2 ORF2 polypeptide used in the immunogenic composition of the present invention can be prepared by any method, including isolation and purification of PCV2 ORF2, conventional protein synthesis, and recombinant methods. Preferred methods for preparing the PCV2 ORF2 polypeptide are described herein above and are also presented in US Patent Application Serial No. 11/034797, the explanations and contents of which are incorporated herein by reference. Briefly, susceptible cells are infected with a recombinant viral vector containing the PCV2 ORF2 DNA coding sequence, the PCV2 ORF2 polypeptide is expressed by a recombinant virus, the expressed PCV2 ORF2 polypeptide is isolated from the supernatant by filtration and inactivated by any conventional method, preferably using a binary ethyleneimine, which is then neutralized to stop the process. inactivation.

Thus, in a further aspect, the immunogenic composition comprises i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, and ii) at least a portion of the viral vector expressing said PCV2 ORF2 protein, preferably a recombinant baculovirus. Moreover, in a further aspect, the immunogenic composition comprises i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, ii) at least a portion of a viral vector expressing said PCV2 ORF2 protein, preferably a recombinant baculovirus, and iii) a portion cell culture supernatant.

In a specific embodiment of the method for preparing and isolating the PCV2 ORF2 protein, the cell culture supernatant is filtered through a membrane with a pore size of preferably between about 0.45-1 μm. Thus, an additional aspect relates to an immunogenic composition comprising i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, ii) at least a portion of the viral vector expressing said PCV2 ORF2 protein, preferably a recombinant baculovirus, and iii) part of the cell culture; where approximately 90% of the components are less than 1 micron in size.

In an additional aspect, the present invention relates to an immunogenic composition comprising i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, ii) at least a portion of a viral vector expressing said PCV2 ORF2 protein, iii) a cell culture portion, iv ) and an inactivating agent for inactivating a recombinant viral vector, preferably BEI, where approximately 90% of components i) -iii) are less than 1 μm in size. Preferably, BEI is present in concentrations effective to inactivate baculovirus. Effective concentrations are described above.

In an additional aspect, the present invention relates to an immunogenic composition comprising i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, ii) at least a portion of a viral vector expressing said PCV2 ORF2 protein, iii) a cell culture portion, iv ) an inactivating agent for inactivating a recombinant viral vector, preferably a BEI, and v) a neutralizing agent for stopping inactivation mediated by an inactivating agent, where approximately 90% of components i) -iii) have a size rum less than 1 micron. Preferably, if the inactivating agent is BEI, said composition comprises sodium thiosulfate in equivalent BEI amounts.

The polypeptide is introduced into a composition that can be administered to an animal susceptible to PCV2 infection. In preferred forms, the composition may also contain additional components known to those skilled in the art (see also Remington's Pharmaceutical Sciences. (1990). 18th ed. Mack Publ., Easton). In addition, the composition may contain one or more veterinary acceptable carriers. As used herein, a “veterinary acceptable carrier” includes, without exception, all solvents, dispersants, coatings, adjuvants, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents that delay absorption of the agent, and the like.

In a preferred embodiment, the immunogenic composition comprises an PCV2 ORF2 protein, as described herein, preferably at the concentrations described above, as an antigenic component, which is mixed with an adjuvant, preferably carbopol, and physiological saline.

Those skilled in the art will understand that the composition herein may contain known physiologically acceptable sterile solutions suitable for injection. To obtain a ready-to-use solution for parenteral injection or infusion, aqueous isotonic solutions, for example, such as saline or solutions of the corresponding plasma protein, are readily available. In addition, the immunogenic and vaccine compositions of the present invention may contain solvents, isotonic agents, stabilizers, or adjuvants. Solvents may include water, saline, glucose, ethanol, glycerol, and the like. Isotonic agents may include, but are not limited to, sodium chloride, glucose, mannitol, sorbitol, and lactose. Stabilizers include, among others, albumin and alkali metal salts of ethylenediaminetetraacetic acid. Suitable adjuvants are those described herein. Most preferred is the use of carbopol, in particular the use of carbopol 971P, preferably in amounts as described above (for example, from about 500 μg to about 5 mg per dose, even more preferably in an amount of from about 750 μg to about 2.5 mg per dose, and most preferably in an amount of about 1 mg per dose).

Thus, the present invention also relates to an immunogenic composition comprising i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, ii) at least a portion of a viral vector expressing said PCV2 ORF2 protein, iii) a cell culture portion, iv) an inactivating agent to inactivate the recombinant viral vector, preferably, BEI, and v) a neutralizing agent to stop the inactivation mediated by the inactivating agent, preferably sodium thiosulfate in the amounts equiv the covariant quantities BEI; and vi) a suitable adjuvant, preferably carbopol 971, in the amounts described above; where approximately 90% of the components i) -iii) are less than 1 μm in size. In an additional aspect, the immunogenic composition further comprises a pharmaceutically acceptable salt, preferably a phosphate salt in a physiologically acceptable concentration. Preferably, the pH of said immunogenic composition is adjusted to physiological pH, which means between approximately 6.5 and 7.5.

Thus, the present invention also relates to an immunogenic composition containing per ml of i) at least 1.6 μg of the PCV2 ORF2 protein described above, ii) at least a portion of baculovirus expressing said PCV2 ORF2 protein, iii) a cell culture portion, iv) approximately 2-8 mM BEI, v) sodium thiosulfate in amounts equivalent to amounts of BEI; and vi) approximately 1 mg of carbopol 971, and vii) a phosphate salt at a physiologically acceptable concentration; where approximately 90% of components i) -iii) are less than 1 μm in size, and the pH of said immunogenic composition is adjusted to about 6.5-7.5.

The immunogenic compositions may further comprise one or more other immunomodulatory substances, for example, such as interleukins, interferons or other cytokines. Immunogenic compositions may also contain gentamicin and merthiolate. While one skilled in the art can readily determine the amounts and concentrations of adjuvants and additives useful in the context of the present invention, the present invention relates to compositions containing from about 50 μg to about 2000 μg of adjuvant and preferably about 250 μg / ml dose of the vaccine composition . In another preferred embodiment, the present invention relates to vaccine compositions containing from about 1 μg / ml to about 60 μg / ml of antibiotics, and more preferably, less than about 30 μg / ml of antibiotics.

Thus, the present invention also relates to an immunogenic composition comprising i) any of the above PCV2 ORF2 proteins, preferably at the concentrations described above, ii) at least a portion of a viral vector expressing said PCV2 ORF2 protein, iii) a cell culture portion, iv) an inactivating agent for inactivating a recombinant viral vector, preferably BEI, and v) a neutralizing agent for stopping inactivation mediated by an inactivating agent, preferably sodium thiosulfate in amounts equivalent to nth amounts of BEI; vi) a suitable adjuvant, preferably carbopol 971, in the amounts described above; vii) a pharmaceutically acceptable concentration of buffered saline, preferably a phosphate salt, and viii) an antimicrobial active agent; where approximately 90% of the components i) -iii) are less than 1 μm in size.

Surprisingly, the immunogenic composition provided herein was highly stable over a period of 24 months. It has also been found that the immunogenic compositions provided herein comprising a recombinant baculovirus expressed PCV2 ORF2 protein, as presented herein, are very effective in reducing the clinical symptoms associated with PCV2 infections. Surprisingly, immunogenic compositions containing the recombinant PCV2 ORF2 protein expressed in baculovirus as provided herein are more effective than immunogenic compositions containing the whole PCV2 virus in an inactivated form or the isolated PCV2 ORF2 viral antigen. In particular, it was unexpectedly discovered that the recombinant protein ORF2 PCV2 expressed in baculovirus is effective in very low concentrations, which means in concentrations up to 0.25 μg / dose. This unexpectedly high immunogenic potential of the PCV2 ORF2 protein can be further enhanced by the addition of carbopol.

An additional aspect relates to a container containing at least one dose of an immunogenic composition of PCV2 ORF2 protein, as presented here, where one dose contains at least 2 μg of PCV2 ORF2 protein, preferably 2-16 μg of PCV2 ORF2 protein. The specified container may contain 1-250 doses of the immunogenic composition, preferably it contains 1, 10, 25, 50, 100, 150, 200 or 250 doses of the immunogenic composition of the protein ORF2 PCV2. Preferably, each of the containers containing more than one dose of the immunogenic composition of the PCV2 ORF2 protein further comprises an antimicrobial active agent. These agents are, for example, antibiotics, including antibiotics gentamicin and merthiolate, and the like. Thus, in one aspect, the present invention relates to a container containing 1-250 doses of an immunogenic composition of PCV2 ORF2 protein, wherein one dose contains at least 2 μg of PCV2 ORF2 protein and gentamicin and / or merthiolate, preferably from about 1 μg / ml up to about 60 μg / ml antibiotics, and more preferably less than about 30 μg / ml.

An additional aspect relates to a kit containing any of the containers described above and instructions containing information for intramuscular administration of at least one dose of the immunogenic composition of the PCV2 ORF2 protein in piglets to reduce the severity of the clinical symptoms associated with PCV2 infection. Moreover, in a further aspect, said instruction contains information on the second or subsequent administration (s) of at least one dose of the immunogenic composition ORF2 PCV2, wherein the second administration or any subsequent administration occurs at least 14 days after the initial or other past administration. Preferably, said instruction also contains information on the administration of an immunostimulant. Preferably, said immunostimulant should be administered at least twice. Preferably, at least 3, more preferably at least 5, even more preferably at least 7 days elapses between the first and second or any subsequent administration of the immunostimulant. Preferably, the immunostimulant is administered at least 10 days, preferably 15, even more preferably 20, even more preferably at least 22 days after the initial administration of the immunogenic composition of the PCV2 ORF2 protein. A preferred immunostimulant is, for example, saucer hemocyanin (KLH), even more preferably emulsified with Freund's incomplete adjuvant (KLH / ICFA). However, it is understood that any other immunostimulant known to a person skilled in the art can also be used. An “immunostimulant,” as used herein, means any substance or composition that can trigger an immune response, preferably without initiating or enhancing a specific immune response, for example, an immune response against a particular pathogen. Additional instructions are provided for administering the immunostimulant in a suitable dose. Moreover, the kit may also contain a container containing at least one dose of an immunostimulant, preferably one dose of KLH or KLH / ICFA.

Moreover, it was also unexpectedly discovered that the immunogenic potential of the immunogenic composition containing the recombinant protein ORF2 PCV2 expressed in baculovirus, preferably in combination with carbopol, can be further enhanced by the introduction of the IngelVac PRRS MLV vaccine (see Example 5). The clinical signs of PCV2 and manifestations of the disease are greatly increased in the presence of PRRS infection. However, immunogenic compositions and methods of vaccination, as described here, significantly reduced this effect, and more than expected. In other words, they found an unexpected synergistic effect when animals, preferably pigs, were treated with any of the immunogenic compositions of ORF2 PCV2, as presented here, and the Ingelvac PRRS MLV vaccine (Boehringer Ihgelheim).

Thus, in an additional aspect, the present invention relates to a kit, as described above, containing an immunogenic composition of PCV2 ORF2 as described herein, and an instruction where the instruction further comprises administering an immunogenic composition of PCV2 ORF2 together with an immunogenic composition comprising a PRRS antigen, preferably , PRRS antigen with adjuvant. Preferably, the PRRS antigen is IngelVac® PRRS MLV (Boehringer Ingelheim).

In an additional aspect, the present invention also relates to a kit comprising i) a container containing at least one dose of an immunogenic composition of PCV2 ORF2 as provided herein, and ii) a container containing an immunogenic composition comprising a PRRS antigen, preferably an adjuvanted PRRS antigen. Preferably, the PRRS antigen is IngelVac® PRRS MLV (Boehringer Ingelheim). More preferably, the kit further comprises instructions containing information on the administration of both pharmaceutical compositions. Preferably, it contains information that a composition comprising PCV2 ORF2 is administered earlier in time than a composition containing PRRS.

An additional aspect relates to the use of any of the compositions provided herein as a medicine, preferably as a medicine for veterinary medicine, even more preferably as a vaccine. Moreover, the present invention also relates to the use of any of the compositions described herein for the manufacture of a medicament for reducing the severity of clinical symptoms associated with PCV2 infection. Preferably, the medicament is intended to prevent PCV2 infection, even more preferably in piglets.

An additional aspect relates to a method for (i) preventing an infection or reinfection of PCV2, or (ii) reducing or stopping the clinical symptoms caused by PCV2 in a subject, comprising administering any of the immunogenic compositions provided herein to a subject in need thereof. Preferably, the subject is a pig. Preferably, the immunogenic composition is administered intramuscularly. Preferably, a single dose or two doses of the immunogenic composition are administered, wherein one dose preferably contains at least about 2 μg of PCV2 ORF2 protein, even more preferably from about 2 to about 16 μg, and at least from about 0.1 to about 5 mg carbopol, preferably about 1 mg carbopol. An additional aspect relates to a method of treatment as described above, where the second application of the immunogenic composition is included. Preferably, a second administration of the same immunogenic composition is carried out, preferably having the same amount of PCV2 ORF2 protein. Preferably, the second administration is also carried out intramuscularly. Preferably, the second administration is carried out at least 14 days after the initial administration, even more preferably at least 4 weeks after the initial administration.

In an additional aspect, the method of treatment also includes the introduction of an immunostimulant. Preferably, said immunostimulant is administered at least twice. Preferably, at least 3, more preferably at least 5 days, even more preferably at least 7 days pass between the first and second administration of the immunostimulant. Preferably, the immunostimulant is administered at least 10 days, preferably 15, even more preferably 20, even more preferably at least 22 days after the initial administration of the immunogenic composition of PCV2 ORF2. A preferred immunostimulant is, for example, saucer hemocyanin (KLH), even more preferably emulsified with incomplete Freund's adjuvant (KLH / ICFA). However, it is understood that any other immunostimulant known to a person skilled in the art can also be used. The introduction of an immunostimulant in a suitable dose lies in the ordinary competence of a person skilled in the art.

In a further aspect, the method of treatment described above also includes administering a PRRS antigen. Preferably, the PRRS antigen is IngelVac® PRRS MLV (Boehringer Ingelheim). Preferably, said PRRS antigen is administered later in time than the administration of the immunogenic composition of the PCV2 ORF2 protein.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a flowchart for the preferred construction of a recombinant baculovirus with PCV2 ORF2; and

Figures 2a and 2b are a flow chart for preparing a composition of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following examples set forth the preferred materials and methods of the present invention. However, it should be understood that these examples are provided only as an illustration and nothing should be considered limiting the overall scope of the invention.

EXAMPLE 1

In this example, the relative yields of ORF2 are compared using the methods of the present invention and using methods known in the art. In each of the four rotating flasks of 1000 ml, approximately 1.0x10 ⁶ Sf + / ml cells were seeded in 300 ml of Excell 420 insect-free serum medium (JRH Biosciences, Inc., Lenexa, KS). The original cell culture was identified as the original SF + cell strain (Spodoptera frugiperda), passage 19, Lot # N112-095W. The cells used to obtain the parent strain of SF + cells were obtained from Protein Sciences Corporation, Inc., Meriden, CT. The SF + cell line for this example was limited to passages 19 and 59. For the purposes of the present invention, it is possible to work with other passages, however, in order to scale the method up to large-scale production, at least 19 passages may be necessary, and passages after 59 may affect expression although this has not been investigated. In more detail, the initial culture of SF + cells after storage in liquid nitrogen was grown in Excell 420 medium in suspension in sterile rotating flasks with constant shaking. Cultures were grown in rotating flasks from 100 ml to 250 ml with 25-150 ml of serum-free Excell 420 medium. When the cells multiplied to a cell density of 1.0-8.0 × 10 ⁶ cells / ml, they were divided into new flasks with a sieving density of 0 , 5-1.5 × 10 ⁶ cells / ml. Subsequent expanded cultures were grown in rotating flasks up to 36 liters in size or in stainless steel bioreactors up to 300 liters for a period of 2-7 days at 25-29 ° C.

After sieving, the flasks were incubated at 27 ° C for four hours. Then, each flask was seeded with a recombinant baculovirus containing the PCV2 ORF2 gene (SEQ ID NO: 4). A recombinant baculovirus containing the PCV2 ORF2 gene was prepared as follows: the PCV2 ORF2 gene from the North American PCV2 strain was amplified by PCR to contain the Kozak 5'-sequence (SEQ ID NO: 1) and the EcoR1 3'-region (SEQ ID NO: 2) , cloned into the pGEM-T-Easy vector (Promega, Madison, WI). It was then sequentially excised and subcloned into the pVL1392 transfer vector (BD Biosciences Pharmingen, San Diego, CA). The subcloned portion is presented here as SEQ ID NO: 7. Plasmid pVL1392 containing the PCV2 ORF2 gene was designated N47-064Y and then co-transfected with BaculoGold® Baculovirus DNA (BD Biosciences Pharmingen) to Sf + insect cells (Protein Sciences, Meriden, CT) to obtain recombinant baculovirus containing the PCV2 ORF2 gene. The new design is presented here as SEQ ID NO: 8. Recombinant baculovirus containing the PCV2 ORF2 gene was purified by plating to separate plaques, and the original vaccine virus (MSV) was propagated in SF + cell lines, aliquoted and stored at -70 ° C. MSV was positively identified as baculovirus with PCV2 ORF2 by PCR-RFLP using baculovirus-specific primers. Insect cells infected with baculovirus with PCV2 ORF2 to produce MSV or a working vaccine virus expressed the PCV2 ORF2 antigen, then were detected by polyclonal serum or monoclonal antibodies in an indirect assay with a fluorescent antibody. In addition, the identity of baculovirus with ORV2 PCV2 was confirmed by sequencing of N-terminal amino acids. Baculovirus MSV with ORF2 PCV2 was also tested for purity according to 9 C.F.R. 113.27 (s), 113.28 and 113.55. All recombinant baculoviruses seeded in rotating flasks had different infection rates (MOIs). 7.52 ml of inoculum was inoculated into flask 1 with a MOI of 0.088; 3.01 ml of inoculum was inoculated into flask 2 with a MOI of 0.36; 1.5 ml of inoculum was seeded into flask 3 with a MOI of 0.18; and 0.75 ml inoculum was inoculated into flask 4 with a MOI of 0.09. A flow diagram illustrating the main steps used to construct a recombinant baculovirus with PCV2 ORF2 is shown here as Figure 1.

After inoculation with baculovirus, the flasks were then incubated at 27 ± 2 ° C for 7 days and during this time also shook at 100 rpm. Ventilated flask caps were used to provide airflow. Samples were taken from each flask every 24 hours for the next 7 days. After isolation, each sample was centrifuged, the precipitate and supernatant were separated, and then microfiltered through a membrane with a pore size of 0.45-1.0 μm.

Then, in the obtained samples, it was necessary to estimate the amount of ORF2 present in them by ELISA. An ELISA was performed with capture antibody - anti-PCV2 IgG pig Pab, purified using protein G (diluted 1: 250 in PBS), diluted to 1: 6000 in 0.05 M carbonate buffer (pH 9.6). Then 100 μl of the antibody was placed in the wells of a microtiter plate, sealed and incubated overnight at 37 ° C. The plate was then washed three times with a washing solution containing 0.5 ml Tween 20 (Sigma, St. Louis, MO), 100 ml 10X D-PBS (Gibco Invitrogen, Carlsbad, CA) and 899.5 ml of distilled water. 250 μl of blocking solution (5 g Carnation non-skimmed milk powder (Nestle, Glendale, CA) in 10 ml of D-PBS QS to 100 ml of distilled water) was successively added to each well. The next step was washing the test plate and then adding pre-diluted antigen. Pre-diluted antigen was prepared by adding 200 μl of dilution solution (0.5 ml Tween 20 in 999.5 ml D-PBS) to each well of a dilution plate. The sample was then diluted in a ratio of 1: 240 and in a ratio of 1: 480, and 100 μl of each of these diluted samples was then added to one of the upper wells of the dilution plate (i.e., 100 μl of a 1: 240 dilution was added to one upper well and 100 μl of a dilution of 1: 480) was added to another). Serial dilutions were then performed for the rest of the plate by withdrawing 100 μl from each subsequent well and transferring to the next well in the plate. Each well was mixed before performing the next transfer. Rinsing the test tablet included washing the tablet three times with rinsing buffer. The plate was then sealed and incubated for one hour at 37 ° C before washing three more times with washing buffer. The antibody used for detection was a monoclonal antibody to PCV ORF2. It was diluted to 1: 300 in a dilution solution, and then 100 μl of the diluted antibody for detection was added to the wells. The plate was then sealed and incubated for one hour at 37 ° C before washing three times with washing buffer. The conjugate diluent was then prepared by adding normal rabbit serum (Jackson Immunoresearch, West Grove, PA) to the dilution solution to a concentration of 1%. Conjugated goat anti-mouse antibody (H + 1) -HRP (Jackson Immunoresearch) was diluted in conjugate diluent to 1: 10000. Then, 100 μl of the diluted conjugated antibody was added to each well. The plate was then sealed and incubated for 45 minutes at 37 ° C before washing three times with washing buffer. 100 μl of substrate (TMB peroxidase substrate, Kirkgaard and Perry Laboratories (KPL), Gaithersberg, MD) mixed with an equal volume of peroxidase B substrate (KPL) was added to each well. The plate was incubated at room temperature for 15 minutes. Then, 100 μl of 1 N HCl solution was added to all wells to stop the reaction. The plate was then scanned on a spectrophotometer to read the plates after ELISA. The results of this analysis are presented in table 1 below:

Table 1 Day Flask Precipitate ORF2 (μg) ORF2 in the supernatant (mcg)

3 one 47.53 12 3 2 57.46 22 3 3 53.44 fourteen 3 four 58.64 12 four one 43.01 44 four 2 65.61 62 four 3 70.56 32 four four 64.97 24 5 one 31.74 one hundred 5 2 34.93 142 5 3 47.84 90 5 four 55.14 86 6 one 14.7 158 6 2 18.13 182 6 3 34.78 140 6 four 36.88 146 7 one 6.54 176 7 2 12.09 190 7 3 15.84 158 7 four 15.19 152

These results show that with prolonged incubation time, the expression of ORF2 in the supernatant of centrifuged cells and medium is greater than the expression in the pellet of centrifuged cells and medium. Accordingly, allowing the expression of ORF2 for at least 5 days and isolating it from the supernatant compared to allowing expression of less than 5 days and isolating ORF2 from cells leads to a large increase in ORF2 yield and a significant improvement over previous methods.

EXAMPLE 2

This example presents data on the effectiveness of the invention claimed in the claims in this document. Approximately 1.0 × 10 ⁶ Sf + / ml cells were seeded in a 1000 ml rotating flask in 300 ml of Excell 420 medium. The flask was then incubated at 27 ° C and shaken at 100 rpm. Then, 10 ml of inoculation of the PCV2 / Bac p + 6 ORF2 virus (recombinant baculovirus containing the PCV2 ORF2 gene, passaged an additional 6 times in Sf9 insect cells) was inoculated into the flask with 0.1 MOI after 24 hours of incubation.

Then the flask was incubated at 27 ° C for only 6 days. After incubation, the flask was centrifuged, and three samples of the obtained supernatant were collected and inactivated. The supernatant was inactivated by adjusting its temperature to 37 ± 2 ° C. To the first sample of the supernatant was added a 0.4 M solution of 2-bromoethylenamine hydrobromide cyclized to 0.2 M binary ethyleneimine (BEI) in 0.3 n NaOH until a final BEI concentration of 5 mM was obtained. 10 mM BEI was added to the second supernatant sample. No BEI supernatant was added to the third sample. Samples were continuously stirred for 48 hours. To neutralize all residual BEI, a 1.0 M sodium thiosulfate solution was added until a final minimum concentration of 5 mM was obtained. Then, the amount of ORF2 in each sample was evaluated using the same ELISA as described in Example 1. The results of this can be seen in Table 2 below:

table 2 Sample ORF2 in the supernatant (mcg) one 78.71 2 68.75 3 83.33

In this example, it was shown that neutralization with BEI does not remove or degrade significant amounts of the protein product of recombinant ORF2 PCV2. This confirms the absence of a large loss of ORF2 in the supernatant due to BEI or elevated temperatures. Those skilled in the art will understand that the isolated ORF2 is a stable protein product.

EXAMPLE 3

This example shows that the present invention can be scaled from small-scale production of recombinant ORF2 PCV2 to large-scale production of recombinant ORF2 PCV2. 5.0 × 10 ⁵ cells / ml SF + / ml cells in 7000 ml of ExCell 420 medium were seeded in 20,000 ml Applikon bioreactor. Then the cells and the medium were incubated at 27 ° C and shaken at 100 rpm./min for the next 68 hours. At the 68th hour, 41.3 ml of MSV + 3 baculovirus with ORF2 PCV2 was added to 7000 ml of ExCell 420 medium. Then the resulting mixture was added to the bioreactor. Over the next seven days, the mixture was incubated at 27 ° C and rocked at 100 rpm. Samples from the bioreactor were taken every 24 hours starting from day 4 after infection, and each sample was centrifuged. The supernatant from the samples was retained, and then the amount of ORF2 was evaluated using densitometry after SDS-PAGE. The results of this can be seen in table 3 below:

Table 3 Day after infection ORF2 in the supernatant (μg / ml) four 29.33 5 41.33 6 31.33 7 60.67

EXAMPLE 4

In this example, the efficacy of seven candidate vaccines was tested and efficacy parameters were additionally determined after exposure to the virulent strain of PCV2. One hundred and eight (108) cesarean-removed, non-colostrum (CDCD) piglets aged 9-14 days were randomly assigned to 9 groups of equal size. Table 4 describes the general structure of the study for this example.

Table 4. General structure of the study Group Number of piglets Treatment Processing day KLH / ICFA on day 21 or day 27 24-day virulent PCV2 infection Day autopsy 49 one 12 PCV2 vaccine No. 1 - (vORF2 16 mcg) 0 + + + 2 12 PCV2 vaccine No. 2 - (vORF2 8 mcg) 0 + + +

3 12 PCV2 vaccine No. 3 - (vORF2 4 mcg) 0 + + + four 12 PCV2 vaccine No. 4 - (rORF2 16 mcg) 0 + + + 5 12 PCV2 vaccine No. 5 - (rORF2 8 mcg) 0 + + + 6 12 PCV2 vaccine No. 6 - (rORF2 4 mcg) 0 + + + 7 12 PCV2 vaccine No. 7 - (killed virus with whole cells) 0 + + + 8 12 No - Contamination Controls N / a + + + 9 12 No - Strict Group
negative control N / a + - + vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture

In seven of the groups (groups 1–7), doses of ORF2 PCV2 polypeptide were administered, one of the groups served as an infection control and did not receive ORF2 PCV2, and the other group served as a strict negative control group and also received ORF2 PCV2. At day 0, groups 1 to 7 were treated with the prescribed vaccines. Piglets in group 7 were secondary treated on day 14. The piglets were examined for adverse events and reactions at the injection site after vaccination, and on day 19 the piglets were transferred to the second study center. In the second study center, groups 1–8 were groups contained in the same building, while group 9 was kept in a separate building. All piglets were injected with saucer hemocyanin (KLH) / Freund's incomplete adjuvant (ICFA) on days 21 and 27, and on day 24, groups 1-8 were infected with virulent PCV2.

Blood samples were collected before and after infection for PCV2 serology. After infection, body weight data were collected to determine average daily weight gain (ADWG), clinical symptom data, and nasal swab samples to determine nasal secretion of PCV2. On day 49, all surviving piglets were opened, lung lesions were evaluated, and selected tissues were fixed in formalin for immunohistochemical (IHC) testing later.

Materials and methods

This was a partially blind vaccination-infection feasibility study performed on CDCD piglets aged 9-14 days per day 0. PCA2 IFA titers in sows for inclusion in the study were ≤1: 1000. In addition, the serological status of the sows came from a known PRRS-negative herd. Twenty-eight (28) sows were tested for serological status for PCV2. For fourteen (14), PCV2 ≤1000 was shown and transferred to the first research center. One hundred and ten (110) piglets were removed by caesarean section, and they were available for this study at day -4. 108 CDCD pigs on day -3 in the first study center were weighed, labeled with ear tags, grouped by weight and randomly assigned to groups 1-9, as described in table 4. If any animal that meets the inclusion criteria was registered for the study, and then expelled for any reason, the researcher and controller consulted to determine the applicability of the data collected for this animal in the final analysis. The date of exclusion of registered piglets and the reason for the exception were documented. In the initial stage, none of the sows were excluded. Only 108 of the available 110 piglets were randomly recorded in one of 9 groups on day-3. The two smallest piglets (nos. 17 and 19) were not recorded in the group, and they were available as additional ones if necessary. During the study, several animals were excluded. Piglet 82 (group 9) for day -1, piglet No. 56 (group 6) for day 3, piglet No. 53 (group 9) for day 4, piglet No. 28 (group 8) for day 8, piglet No. 69 (group 8 ) on day 7, and piglet No. 93 (group 4) on day 9, all were found dead before infection. These six piglets were not included in the final results of the study. Piglet No. 17 (one of the additional piglets) was recorded in group 9. The remaining additional piglet No. 19 was excluded from the study.

The formulations administered in each of the groups were as follows: Group 1 was intended to administer 1 ml of viral ORF2 (vORF2) containing 16 μg ORF2 / ml. This was accomplished by mixing 10.24 ml of viral ORF2 (256 μg / 25 μg / ml = 10.24 ml of vORF2) with 3.2 ml of 0.5% carbopol and 2.56 ml of phosphate-buffered saline with a pH of 7.4. So received 16 ml of the composition for group 1. Group 2 was intended for the introduction of 1 ml of vORF2 containing 8 μg of vORF2 / ml. This was accomplished by mixing 5.12 ml of vORF2 (128 μg / 25 μg / ml = 5.12 ml of vORF2) with 3.2 ml of 0.5% carbopol and 7.68 ml of phosphate-buffered saline with a pH of 7.4. So got 16 ml of the composition for group 2. Group 3 was intended for the introduction of 1 ml of vORF2 containing 4 μg of vORF2 / ml. This was done by mixing 2.56 ml of vORF2 (64 μg / 25 μg / ml = 2.56 ml of vORF2) with 3.2 ml of 0.5% carbopol and 10.24 ml of phosphate-buffered saline with a pH of 7.4. So received 16 ml of the composition for group 3. Group 4 was intended for the introduction of 1 ml of recombinant ORF2 (rORF2) containing 16 μg rORF2 / ml This was accomplished by mixing 2.23 ml of rORF2 (512 μg / 230 μg / ml = 2.23 ml of rORF2) with 6.4 ml of 0.5% carbopol and 23.37 ml of phosphate-buffered saline with a pH of 7.4. Thus, 32 ml of the composition for group 4 was obtained. Group 5 was intended for the administration of 1 ml of rORF2 containing 8 μg rORF2 / ml. This was accomplished by mixing 1.11 ml rORF2 (256 μg / 230 μg / ml = 1.11 ml rORF2) with 6.4 ml 0.5% carbopol and 24.49 ml phosphate-buffered saline with a pH of 7.4. Thus, 32 ml of the composition for group 5 was obtained. Group 6 was designed to administer 1 ml of rORF2 containing 8 μg rORF2 / ml. This was accomplished by mixing 0.56 ml of rORF2 (128 μg / 230 μg / ml = 0.56 ml of rORF2) with 6.4 ml of 0.5% carbopol and 25.04 ml of phosphate-buffered saline with a pH of 7.4. So we got 32 ml of the composition for group 6. Group 7 was intended for the introduction of 2 ml of killed whole-cell vaccine PCV2 (PCV2 KV) containing MAX PCV2 KV. This was accomplished by mixing 56 ml of PCV2 KV with 14 ml of 0.5% carbopol. So received 70 ml of the composition for group 7. Finally, group 8 was intended for the introduction of 0.5 μg / ml or 1.0 μg / ml KLH per dose of 2 ml. This was accomplished by mixing 40.71 ml of KLH (7.0 μg protein / ml at 0.5 μg / ml = 570 ml (7.0 μg / ml) (x) = (0.5) (570 ml)), 244 , 29 ml of phosphate-buffered saline with a pH of 7.4 and 285 ml of Freund's adjuvant. Table 5 describes the time frames for the key operations of this example.

Table 5. Research Operations Day study Research operations -4, 0-49 General examinations for general health and clinical features -3 Weighed Randomly assigned to groups; Blood samples were collected from all piglets 0 Health examination; IVP No. 1-7 was administered to groups 1-7, respectively 0-7 The piglets were examined for reactions at the infection site. fourteen Secondary administration of PCV2 No. 7 vaccine in group 7 was performed; Blood samples from all piglets 14-21 Group 7 was examined for reactions in the infection site. 16-19 All piglets were treated with antibiotics (data not available)

19 Piglets were transported from the first testing center to the second testing center 21 Treated groups 1-9 KLH / ICFA 24 Blood samples and nasal swabs from all piglets were collected; all piglets were weighed; infected groups 1-8 with PCV2 infection material 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47 Samples of nasal swabs from all piglets were collected. 27 Treated groups 1-9 KLH / ICFA 31 Blood samples were collected from all piglets 49 Blood samples and nasal swabs from all piglets were collected; All piglets were weighed; All piglets were opened; Macroscopic lesions were noted with greater severity of jaundice and stomach ulcers; Damage to the lungs was evaluated; Preserved fresh and fixed formalin samples; Completed the intravital phase of the study

After completion of the intravital phase of the study, formalin-fixed tissues were evaluated by a pathologist by means of immunohistochemistry (IHC) for detection of PCV2 antigen, PCV2 in blood samples, serologically evaluated, PCV2 release in nasal smear samples was evaluated, and average weight gain (ADWG) from 24 days to 49 days was determined.

In the first research center, animals were kept in individual cages in five rooms from birth to about 11 days of age (approximately 0 days of the study). All rooms were identical in layout and contained racks with individual stainless steel cages with heated and filtered air, delivered separately to each individual unit. Each room had its own heating and ventilation, thus preventing cross-contamination of air between the rooms. In a second research center, animals were kept in two different buildings. Group 9 (strict negative control group) was kept separately in the converted carving building, and groups 1-8 were kept in the converted room for young animals. Each group was kept in a separate pen (11-12 pigs per pen), and approximately 3.0 square feet per piglet was provided in each pen. Each paddock was on a raised floor with plastic flooring. The recess under the pens served as a reservoir for excrement and garbage. Each building had its own heating and ventilation systems, with little chance of cross-contamination of air between buildings.

In the first research center, piglets were fed a specially formulated milk diet from birth to about 3 weeks of age. By 19 days (approximately 4 ½ weeks of age), all piglets consumed a solid, specially mixed diet. In the second research center, all piglets were fed a custom-made, drug-free, commercial mixed diet suitable for their age and weight, as desired. Water at both research centers was also available at will.

All test piglets were given vitamin E at day -2, with iron injections at day -1, and with NAXCEL® (1.0 ml, IM, in changing hips) on day 16, 17, 18 and 19. In addition, piglet No. 52 (group 9) were injected with iron on day 3, piglet 45 (group 6) were injected with iron on day 11, piglet No. 69 (group 8) was injected with NAXCEL® on day 6, piglet No. 74 (group 3) was injected with dexamethasone and penicillin on day 14, and piglet No. 51 (group 1) was injected with dexamethasone and penicillin on day 13 and NAXCEL® on day 14 for various medical reasons.

At this time, in both research centers, the piglets were monitored by a veterinarian. An animal health survey was performed on day 0 and documented in the form of a health survey record. All animals had good health and nutritional status, as determined by examination on day 0. All tested animals, as examined, were in good health and nutritional status before infection. Skeletons and tissues were disposed of in a burner. The last placement of the test animals was recorded in the protocol of the placement of animals.

On day 0, piglets in groups 1-6 were injected with 1.0 ml of PCV2 1-6 vaccines, respectively, IM in the left neck area using a sterile 3.0 ml Luer tip syringe and a 20g × ½ "sterile needle. , recorded in group 7, was injected with 2.0 ml of PCV2 No. 7 IM vaccine in the left neck area using a sterile 3.0 ml Luer tip syringe and a 20g × ½ "sterile needle. On day 14, piglets recorded in group 7 were injected with 2.0 ml of PCV2 No. 7 IM vaccine in the neck area to the right using a sterile 3.0 ml syringe with Luer tip and a 20g × ½ ”sterile needle.

On day 21, all test piglets were injected with 2.0 ml KLH / ICFA IM into the right thigh using a sterile 3.0 ml Luer-tip syringe and a 20g × 1 sterile needle. On day 27, 2.0 ml of KLH / ICFA to the left thigh using a sterile 3.0 ml syringe with Luer tip and a 20g × 1 "sterile needle.

On day 24, piglets recorded in groups 1-8 were injected with 1.0 ml of material for PCV2 infection ISUVDL (5.11 log ₁₀ TCID ₅₀ / ml) IM in the left neck using a sterile 3.0 ml syringe with Luer tip and 20g × 1 "sterile needle. An additional 1.0 ml of the same material was injected IN into each piglet (0.5 ml per nostril) using a sterile 3.0 ml syringe with Luer tip and nasal cannula.

The tested animals were examined daily according to the general state of health and the presence of adverse events on days -4 and from 0 days to 19 days. The examinations were documented in the clinical examination protocol. All test piglets were examined from 0 days to 7 days, and in group 7 on days 14-21, the reactions at the injection site were additionally examined. The average weight gain was determined by weighing each piglet on a calibration scale for days -3, 24 and 49, or for a day in which the piglet was found dead after infection. Body weight was recorded in the form of body weight. A body weight of -3 days was used to separate the piglets into groups before randomization. Mass data for 24 days and 49 days was used to determine the average daily weight gain (ADWG) for each pig during these time points. For piglets who died after infection and before 49 days, ADWG was customized to represent ADWG from 24 days to the day of death.

For serological determination of PCV2, whole blood was taken from a vein from orbital venous sinuses on days -3 and 14 for each piglet. Blood was drawn from each orbit from an orbital venous sinus by introducing a sterile capillary tube into the midline of the palpebral fissure of one of the eyes and drawing about 3. 0 ml whole blood in a 4.0 ml serum separation tube (SST). On days 24, 31, and 49, whole venous blood was collected from each anterior vena cava pig using a sterile needle for an 18 g × 1½ "vacuum container (Becton Dickinson and Company, Franklin Lakes, New Jersey), a needle holder for a vacuum container, and 13 ml SST Blood samples at each time point were recorded in a sample collection protocol. Blood was allowed to clot at each SST, then each SST was centrifuged and serum collected. The collected serum was transferred to a sterile snap-on tube and stored at -70 ± 10 ° C until testing at late d ate. In serum samples, BIVI-R & D staff tested the presence of antibodies to PCV2.

In piglets once a day from 20 days to 49 days, clinical symptoms were observed, and clinical examinations were documented in the protocol of clinical examinations.

To test nasal secretion of PCV2, on days 24, 25, and then on every day of the study with an odd number up to day 49 inclusive, a sterile dacron swab was injected intranasally into either the left or right nostril of each pig (one swab per pig) so sterile as far as possible, smeared with a circle for several seconds and then removed. Each swab was then placed in a separate sterile snap-on tube containing 1.0 ml of EMEM with 2% IFBS, 500 units / ml penicillin, 500 μg / ml streptomycin and 2.5 μg / ml fungizon. The swab in the test tube was divided into parts, the latched test tube was sealed and the animal number, study number, date of selection, study day and “nasal swab” were indicated on the label accordingly. The sealed snap-on tubes were kept at -40 ± 10 ° C until transported overnight in ice on the BIVI-St. Joseph. Nasal sampling was documented in the form of nasal swab collection. BIVI-R & D tested the quantitative isolation of the PCV2 virus (VI) in nasal swab samples. The results were expressed in log ₁₀ values. A value of 1.3 log or less was considered negative, and any value of more than 1.3 log was considered positive.

Piglets (No. 28, 52, 56, 69, 82, and 93) who died in the first center of the study were opened at the level necessary to determine the diagnosis. Macroscopic lesions were documented and tissues from these piglets were not preserved. In the second center of the study, autopsies were performed on piglets who died before 49 days (No. 45, 23, 58, 35), piglets found dead 49 days before euthanasia (No. 2, 43) and piglets euthanized on day 49. Any macroscopic lesions were noted, and the percentage of lung lobes with lesions was documented in the form of an autopsy report.

From each of the 103 piglets opened in the second center of the study on a sample of tissue from the tonsil, lung, heart, liver, mesenteric lymph node, kidney and inguinal lymph node were placed in a separate container with buffered 10% formalin; at the same time, another tissue sample from the above organs was placed in a centrifugation bag (M-Tech Diagnostics Ltd., Thelwall, UK) and each centrifugation bag was placed in ice. Each container was labeled accordingly. Sample collection was documented in the form of an autopsy protocol. Formalin-fixed samples and a diagnostic request form were then accepted for IHC testing. IHC testing was carried out according to standard ISU laboratory methods for obtaining samples, sample preparation and glass and staining methods. Fresh samples in centrifugation bags were sent along with ice bags to the study controller for storage (-70 ° ± 10 ° C) and possible future use. Formalin-fixed tissues were examined by a pathologist to detect PCV2 by IHC and evaluated using the following scoring system: 0 = none; 1 = limited positive staining, few patches; 2 = moderate positive staining, multiple patches; and 3 = profuse positive staining, spread throughout the tissue. Due to the fact that the pathologist could not definitely distinguish inguinal LN from mesenteric LN, the results for these tissues were simply labeled as a lymph node, and this score for the animal was the highest score for each of the two tissues.

results

The results for this example are shown below. It was noted that one pig from group 9 died before days 0, and another 5 piglets died after vaccination (1 pig from group 4; 1 pig from group 6; 2 pigs from group 8; and 1 pig from group 9). A post mortem examination revealed that all six died due to serious infections not related to vaccination or PMWS. In addition, no adverse events or reactions were detected in the injection site in any of the groups.

The results of average weight gain (ADWG) are presented below in table 6. Group 9, the strict negative control group, had the highest ADWG (1.06 ± 0.17 pounds / day), followed by group 5 (0.94 ± 0, 22 lbs / day), which was administered a single dose of 8 μg rORF2. Group 3, in which a single dose of 4 μg vORF2 was administered, had the lowest ADWG (0.49 ± 0.21 pounds / day), followed by group 7 (0.50 ± 0.15 pounds / day), in which 2 doses of the killed vaccine were administered.

Table 6. Summarization of the average daily weight gain in groups (ADWG) Group Impact N ADWG - pounds / day (day 24 - day 49) or with substitution for piglets who died before 29 days one vORF2 - 16 mcg (1 dose) 12 0.87 ± 0.29 pounds / day 2 vORF2 - 8 mcg (1 dose) 12 0.70 ± 0.32 pounds / day 3 vORF2 - 4 mcg (1 dose) 12 0.49 ± 0.21 pounds / day four rORF2 - 16 mcg (1 dose) eleven 0.84 ± 0.30 pounds / day 5 rORF2 - 8 mcg (1 dose) 12 0.94 ± 0.22 lbs / day 6 rORF2 - 4 mcg (1 dose) eleven 0.72 ± 0.25 pounds / day 7 KV (2 doses) 12 0.50 ± 0.15 lbs / day 8 Infection controls 10 0.76 ± 0.19 pounds / day 9 Strict negative controls eleven 1.06 ± 0.17 pounds / day vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture

Serological results for PCV2 are presented below in table 7. All nine groups were PCV2 seronegative at day -3. On day 14, the groups that were injected with vORF2 vaccines had the highest titers, ranging from 187.5 to 529.2. Piglets after administration of the killed viral vaccine had the following of the highest titers, after the rORF2 vaccine administration groups. Groups 8 and 9 remained seronegative by this time. On day 24 and day 31, for piglets after administration of the vORF2 vaccine, they continued to show a strong serological response, following closely the group with the introduction of two doses of killed virus vaccine. Pigs with rORF2 vaccines responded more slowly serologically, while groups 8 and 9 continued to be seronegative. On day 49, for piglets with the vORF2 vaccine, 2 doses of the killed viral vaccine and the lowest dose of rORF2 showed the strongest serological responses. Piglets administered with 16 μg and 8 μg rORF2 vaccines had slightly higher titers in IFA than infection controls. For group 9, day 49 showed a strong serological response.

Table 7. Summary of PCV2 titers in IFA in groups
IFA TITLE Group Impact Day -3 Day 14 Day 24 Day 31 ** Day 49 *** one vORF2 - 16 mcg (1 dose) 50,0 529.2 4400.0 7866.7 11054.5 2 vORF2- 8 mcg (1 dose) 50,0 500,0 3466.7 6800.0 10181.8 3 vORF2- 4 mcg (1 dose) 50,0 187.5 1133.3 5733.3 9333.3 four rORF2- 16 mcg (1 dose) 50,0 95.5 1550.0 3090.9 8000.0 5 rORF2- 8 mcg (1 dose) 50,0 75.0 887.5 2266.7 7416.7 6 rORF2- 4 mcg (1 dose) 50,0 50,0 550.0 3118.2 10570.0 7 KV (2 doses) 50,0 204.2 3087.5 4620.8 8680.0

8 Infection controls 50,0 55.0 50,0 50,0 5433.3 9 Strict negative controls 50,0 59.1 59.1 54.5 6136.4 vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture
* For the purpose of calculation, the titer in IFA ≤100 was designated as the titer “50”; an IFA titer of ≥6400 was designated as an IFA titer of “12800”.
** Day of infection
*** Day Showdown

The results of clinical examinations after infection are presented below in table 8. This summary of the results includes observations of abnormal behavior, abnormal breathing, coughing and diarrhea. Table 9 contains the results of a generalization of the general frequency of clinical symptoms in groups, and Table 10 contains the results of a generalization of the mortality rate from a summary of the mortality levels in the groups after infection. The most common clinical symptom found in this study was abnormal behavior, which was rated as mild to severe inhibition. Piglets after administration of 2 lower doses of vORF2, piglets after administration of 16 μg rORF2 and piglets after administration of 2 doses of KV vaccine had a manifestation rate of ≥27.3%. Piglets after administration of 8 μg rORF2 and the strict negative control group did not exhibit abnormal behavior. None of the piglets in this study showed any abnormal breathing. Cough was often found in all groups (0–25%), as was diarrhea (0–20%). None of the symptoms detected were pathognomonic for PMWS.

The overall incidence of clinical symptoms varied between groups. Groups after administration of any of the vORF2 vaccines, the group after administration of 16 μg rORF2, the group after administration of 2 doses of the KV vaccine, and the control group had the highest rate of manifestation of common clinical symptoms (≥36.4%). The strict negative control group, the group after administration of 8 μg rORF2 and the group after administration of 4 μg rORF2 had a common clinical symptom rate of 0%, 8.3% and 9.1%, respectively.

Overall mortality rates also varied between groups. The group after administration of 2 doses of the vaccine had the highest mortality rate (16.7%); while the groups after administration of 4 μg vORF2, 16 μg rORF2 or 8 μg rORF2, and the strict negative control group all had 0% mortality rates.

Table 8. Summary of observations in groups of abnormal behavior, abnormal breathing, coughing and diarrhea Group Impact N Abnormal behavior ¹ Abnormal behavior ² Cough ³ Diarrhea ⁴ one vORF2 - 16 mcg (1 dose) 12 2/12
(16.7%) 0/12
(0%) 3/12
(25%) 2/12
(16.7%) 2 vORF2 - 8 mcg (1 dose) 12 4/12
(33.3%) 0/12
(0%) 1/12
(8.3%) 1/12
(8.3%) 3 vORF2 - 4 mcg (1 dose) 12 8/12
(66.7%) 0/12
(0%) 2/12
(16.7%) 1/12
(8.3%) four rORF2 - 16 mcg (1 dose) eleven 3/11
(27.3%) 0/11
(0%) 0/11
(0%) 2/11
(18.2%) 5 rORF2 - 8 mcg (1 dose) 12 0/12
(0%) 0/12
(0%) 1/12
(8.3%) 0/12
(0%) 6 rORF2 - 4 mcg (1 dose) eleven 1/11
(9.1%) 0/11
(0%) 0/11
(0%) 0/12
(0%)

7 KV (2 doses) 12 7/12
(58.3) 0/12
(0%) 0/12
(0%) 1/12
(8.3%) 8 Infection controls 10 1/10
(10%) 0/10
(0%) 2/10
(twenty%) 2/10
(twenty%) 9 Strict negative controls eleven 0/11
(0%) 0/11
(0%) 0/11
(0%) 0/11
(0%) vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture
¹ The total number of piglets in each group for which any abnormal behavior was shown for at least one day
² The total number of piglets in each group for which any abnormal breathing was shown for at least one day
³ The total number of piglets in each group for whom a cough was shown for at least one day
⁴ The total number of piglets in each group for which diarrhea was shown for at least one day

Table 9. Generalization of the overall incidence of clinical symptoms Group Impact N The proportion of piglets with clinical symptoms ¹ Frequency of manifestation one vORF2 - 16 mcg (1 dose) 12 5 41.7% 2 vORF2 - 8 mcg (1 dose) 12 5 41.7%

3 vORF2 - 4 mcg (1 dose) 12 8 66.7% four rORF2 - 16 mcg (1 dose) eleven four 36.4% 5 rORF2 - 8 mcg (1 dose) 12 one 8.3% 6 rORF2 - 4 mcg (1 dose) eleven one 9.1% 7 KV (2 doses) 12 7 58.3% 8 Infection controls 10 four 40% 9 Strict negative controls eleven 0 0% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture
¹ Total number of piglets in each group for which any clinical symptoms were shown for at least one day

Table 10. Generalization of mortality in groups after infection Group Impact N Dead after infection Mortality rate one vORF2 - 16 mcg (1 dose) 12 one 8.3% 2 vORF2 - 8 mcg (1 dose) 12 one 8.3%

3 vORF2 - 4 mcg (1 dose) 12 0 0% four rORF2 - 16 mcg (1 dose) eleven 0 0% 5 rORF2 - 8 mcg (1 dose) 12 0 0% 6 rORF2 - 4 mcg (1 dose) eleven one 9.1% 7 KV (2 doses) 12 2 16.7% 8 Infection controls 10 one 10% 9 Strict negative controls eleven 0 0% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture

The results for nasal isolation of PCV2 are presented below in table 11. After infection on day 24, 1 piglet in group 7 began to isolate PCV2 on day 27. None of the other groups experienced excretion up to 33 days. The main volume of nasal discharge was found from 35 days to 45 days. Groups after administration of any of the three vORF2 vaccines and groups after administration of either 4 or 8 μg rORF2 had the lowest incidence rate of nasal secretion of PCV2 (≤9.1%). The control infection group (group 8) had the highest release rate (80%), followed by the strict negative control group (group 9), which had a manifestation rate of 63.6%.

Table 11. Generalization of the manifestations of nasal secretion of PCV2 in groups Group Impact N The number of piglets with the allocation of at least one day Frequency of manifestation one vORF2 - 16 mcg (1 dose) 12 one 8.3% 2 vORF2 - 8 mcg (1 dose) 12 one 8.3% 3 vORF2 - 4 mcg (1 dose) 12 one 8.3% four rORF2 - 16 mcg (1 dose) eleven 2 18.2% 5 rORF2 - 8 mcg (1 dose) 12 one 8.3% 6 rORF2 - 4 mcg (1 dose) eleven one 9.1% 7 KV (2 doses) 12 5 41.7% 8 Infection controls 10 8 80% 9 Strict negative controls eleven 7 63.6% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture

A summary of the incidence of jaundice in the groups, the incidence of gastric ulcer in the groups, the average estimates of lung damage in the groups, and the frequency of manifestation of lung damage in the groups are shown below in table 12. Six piglets died in the first study center during the study phase after vaccination (group 4, N = 1; group 6, N = 1; group 8, N = 2; group 9, N = 2). Four out of six piglets had fibrinous lesions in one or more body cavities, one piglet (group 6) had lesions associated with clostridial disease, and another piglet (group 9) did not have macroscopic lesions. None of the piglets that died during the stages of the study after vaccination, did not have injuries associated with PMWS.

Piglets who died after infection and piglets euthanized on day 49 were opened. None of the groups at autopsy showed jaundice and stomach ulcers. As for the average% of lung injuries, group 9 had the lowest average% of lung injuries (0%), followed by group 1 with 0.40 ± 0.50% and group 5 with 0.68 ± 1.15%. Groups 2, 3, 7, and 8 had the highest average% lung damage (≥7.27%). Each of these four groups contained one piglet with% lung damage ≥71.5%, which biased the results for these four groups to higher. With the exception of group 9 with the detection of 0% lung damage, the remaining 8 groups had ≤36% lung damage. Almost all detected lung injuries were described as red / purple and consolidated.

Table 12. Generalization of the frequency of manifestations of jaundice in groups, the frequency of manifestations of gastric ulcers in groups, the average% of points of lung damage in groups and the frequency of manifestations of detected lung damage in groups Group Impact Jaundice Stomach ulcers Average% lung damage The frequency of manifestations of detected lung damage one vORF2 - 16 mcg (1 dose) 0/12
(0%) 0/12
(0%) 0.40 ± 0.50% 10/12
(83%) 2 vORF2 - 8 mcg (1 dose) 0/12
(0%) 0/12
(0%) 7.41 ± 20.2% 10/12
(83%) 3 vORF2 - 4 mcg (1 dose) 0/12
(0%) 0/12
(0%) 9.20 ± 20.9% 10/12
(83%) four rORF2 - 16 mcg (1 dose) 0/11
(0%) 0/11
(0%) 1.5 ± 4.74% 4/11
(36%) 5 rORF2 - 8 mcg (1 dose) 0/12
(0%) 0/12
(0%) 0.68 ± 1.15% 9/12
(75%) 6 rORF2 - 4 mcg (1 dose) 0/11
(0%) 0/11
(0%) 2.95 ± 5.12% 7/11
(64%) 7 KV (2 doses) 0/12
(0%) 0/12
(0%) 7.27 ± 22.9% 9/12
(75%) 8 Infection controls 0/10
(0%) 0/10
(0%) 9.88 ± 29.2% 8/10
(80%)

9 Strict negative controls 0/11
(0%) 0/11
(0%) 0/11
(0%) 0/11
(0%) vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; killed whole cell virus = PCV2 virus grown in a suitable cell culture

A summary of the frequency of positive IHC results in the groups is shown in Table 13. Group 1 (vORF2 - 16 μg) and group 5 (rORF2 - 8 μg) had the lowest share of positive IHC results (16.7%). Group 8 (infection controls) and group 9 (strict negative controls) had the highest share of positive IHC results, 90% and 90.9%, respectively.

Table 13. The generalization of the frequency of positive IHC results in groups Group Impact N The number of piglets with at least one positive PCV2 tissue Frequency of manifestation one vORF2 - 16 mcg (1 dose) 12 2 16.7% 2 vORF2 - 8 mcg (1 dose) 12 3 25.0% 3 vORF2 - 4 mcg (1 dose) 12 8 66.7% four rORF2 - 16 mcg (1 dose) eleven four 36.3%

5 rORF2 - 8 mcg (1 dose) 12 2 16.7% 6 rORF2 - 4 mcg (1 dose) eleven four 36.4% 7 KV (2 doses) 12 5 41.7% 8 Infection controls 10 9 90.0% 9 Strict negative controls eleven 10 90.9% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

After infection, group 5, where one dose of 8 μg of the rORF2 antigen was administered, was better than the other 6 groups with the vaccine. Group 5 had the highest ADWG (0.94 ± 0.22 pounds / day), the lowest incidence of abnormal behavior (0%), the second of the lowest incidence of cough (8.3%), the lowest incidence of common clinical symptoms (8.3%), the lowest mortality rate (0%), the lowest percentage of nasal discharge of PCV2 (8.3%), the second of the lowest average% of lung injuries (0.68 ± 1.15%) and the lowest the frequency of manifestation of positive tissues (16.7%). Groups after administration of various levels of rORF2 antigen were generally better than groups after administration of various levels of vORF2, and the group after administration of 2 doses of killed whole-cell PCV2 vaccine was the worst. Tables 14 and 15 summarize the data for groups after infection.

Table 14. Summary of data for post-challenge groups - Part 1 Group N Impact ADWG (pounds / day) Abnormal behavior Cough The overall incidence of clinical symptoms one 12 vORF2 - 16 mcg
(1 dose) 0.87 ± 0.29 2/12 (16.7%) 3/12 (25%) 41.7% 2 12 vORF2 - 8 mcg
(1 dose) 0.70 ± 0.32 4/12 (33.3%) 1/12 (8.3%) 41.7% 3 12 vORF2 - 4 mcg
(1 dose) 0.49 ± 0.21 8/12 (66.7%) 2/12 (16.7%) 66.7% four eleven rORF2 - 16 mcg
(1 dose) 0.84 ± 0.30 3/11 (27.3%) 0/11 (0%) 36.4% 5 12 rORF2 - 8 mcg
(1 dose) 0.94 ± 0.22 0/12 (0%) 1/12 (8.3%) 8.3% 6 eleven rORF2 - 4 mcg
(1 dose) 0.72 ± 0.25 1/11 (9.1%) 0/11 (0%) 9.1% 7 12 Kv
(2 doses) 0.50 ± 0.15 7/12 (58.3) 0/12
(0%) 58.3% 8 10 Infection controls 0.76 ± 0.19 1/10 (10%) 2/10 (20%) 40% 9 eleven Strict negative controls 1.06 ± 0.17 0/11
(0%) 0/11 (0%) 0% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

Table 15. Summary of data for post-challenge groups - Part 2 Group N Impact Mortality rate Nasal discharge Average% lung damage The incidence of at least one PCV2 positive tissue in IHC one 12 vORF2 - 16 mcg
(1 dose) 8.3% 8.3% 0.40 ± 0.50% 16.7% 2 12 vORF2 - 8 mcg
(1 dose) 8.3% 8.3% 7.41 ± 20.2% 25.0% 3 12 vORF2 - 4 mcg
(1 dose) 0% 8.3% 9.20 ± 20.9% 66.7% four eleven rORF2 - 16 mcg
(1 dose) 0% 18.2% 1.50 ± 4.74% 36.3% 5 12 rORF2 - 8 mcg
(1 dose) 0% 8.3% 0.68 ± 1.15% 16.7% 6 eleven rORF2 - 4 mcg
(1 dose) 9.1% 9.1% 2.95 ± 5.12% 36.4% 7 12 Kv
(2 doses) 16.7% 41.7% 7.27 ± 22.9% 41.7% 8 10 Infection controls 10% 80% 9.88 ± 29.2% 90.0% 9 eleven Strict negative controls 0% 63.6% 0/11 (0%) 90.9% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

The results of this study show that all further work on the vaccine should focus on the rORF2 vaccine. In general, nasal secretion of PCV2 was detected after infection, and PCV2 vaccination resulted in a decrease in secretion. The immunohistochemistry of the selected lymphoid tissues also served as a good parameter for the effectiveness of the vaccine, while large differences in ADWG, clinical symptoms, and macroscopic foci between the groups were not found. This study was complicated by the fact that at some point during the study, extraneous PCV2 was introduced, as evident from the nasal secretion of PCV2, PCV2 seroconversion, and IHC-positive tissues in group 9, the strict negative control group.

Discussion

In this study, seven PCV2 vaccines were evaluated, which included three different dose levels of vORF2 antigen administered once per day 0, three different dose levels of rORF2 antigen administered once per day 0 and one dose level of killed whole-cell PCV2 vaccine administered on day 0 and day 14. In general, group 5, which was administered 1 dose of a vaccine containing 8 μg of rORF2 antigen, had the best results. Group 5 had the highest ADWG, the lowest incidence of abnormal behavior, the lowest incidence of abnormal breathing, the second of the lowest incidence of cough, the lowest incidence of common clinical symptoms, the lowest mortality rate, the lowest incidence of nasal discharge of PCV2, the second of the lowest fractions of the average% lung damage and the lowest frequency of manifestation of IHC-positive tissues.

Interestingly, group 4, in which a higher dose of rORF2 antigen was administered than in group 5, did not show the same good or better qualities than group 5. Group 4 had a slightly lower ADWG, a higher incidence of abnormal behavior, a higher incidence of common clinical symptoms, a higher incidence of nasal discharge of PCV2, a higher average% lung damage, and a higher proportion of IHC-positive tissues than group 5. Statistical analyzes that could show that the differences between these the two groups were not statistically significant, they were not performed for these data, but they found a tendency that group 4 did not show the same good qualities as group 5.

After vaccination, 6 piglets died in the first study center. Four out of six piglets came from group 8 or group 9, which were not given vaccines. None of the six piglets showed damage associated with PMWS, adverse events were not described, and in general, all seven vaccines appeared to be safe when administered to piglets at approximately 11 days of age. During the study phase, after vaccination, piglets after administration of either the three-dose vORF2 vaccine or the killed whole-cell vaccine had the highest IFAT levels, while group 5 had the lowest IFAT vaccine levels immediately before infection.

Although this has not been formally proven, it is believed that direct contact is the predominant way of transferring PCV2 to a young pig shortly after weaning from a sow, and an effective vaccine that reduces nasal secretion of PCV2 during production will help control the spread of infection. Groups after administration of one of the three levels of vORF2 antigen and the group after administration of 8 μg rORF2 had the lowest incidence rate of nasal secretion of PCV2 (8.3%). As expected, the infection control group had the highest low incidence of nasal discharge (80%).

Macroscopic lesions in piglets with PMWS secondary to PCV2 infection typically consist of generalized lymphadenopathy in combination with one or more of the following: (1) interstitial pneumonia with interlobular edema, (2) pale skin or jaundice, (3 ) mosaic atrophic liver, (4) stomach ulcers and (5) nephritis. An autopsy of jaundice, hepatitis, nephritis and gastric ulcer was not found for any of the groups, and lymphadenopathy was not specifically examined. The average% degree of lung damage varied between groups. The group after administration of 16 μg of vORF2 had the lowest% degree of lung damage (0.40 ± 0.50%), followed by the group after administration of 8 μg of rORF2 (0.68 ± 1.15%). As expected, the infection control group had the highest average% degree of lung damage (9.88 ± 29.2%). In all four groups, the average% degree of lung damage was elevated due to one pig in each of these groups, which had very high degrees of damage. Most lung lesions have been described as red / purple and consolidated. Typically, PMWS-related lung injuries are described as brown and not deformed by interlobular edema. The lung lesions found in this study were either unrelated to PCV2 infection or a second pulmonary infectious agent could be present. In the context of this study, the% degree of lung damage does not reflect the true measurement of the degree of lung infection due to PCV2.

Other researchers have shown a direct correlation between the presence of the PCH2 antigen by IHC and histopathology. No histopathological examination of selected tissues was performed in this study. Group 1 (16 μg vORF2) and group 5 (8 μg rORF2) had the lowest incidence rate of piglets positive for PCV2 antigen (8.3%), while group 9 (strict negative control group - 90.9%) and group 8 (infection control group - 90.0%) had the highest manifestation rates of piglets positive for PCV2 antigen. Due to the non-subjective nature of this test, IHC results are probably some of the best parameters for judging the effectiveness of a vaccine.

Thus, in one aspect of the present invention, the minimum protective dose (MPD) was determined as 1 ml / 1 dose of a recombinant product with isolated PCV2 ORF2 antigen (rORF2) in a CDCD piglet model at risk of PCV2 infection. Of the three groups, after administration of various levels of rORF2 antigen, group 5 (8 μg of rORF2 antigen) clearly had the highest level of protection. Group 5 either had the best results, or closely adjoined to the most favorable results with respect to all evaluated parameters. When comparing group 5 with the other six groups with the group vaccine after infection, group 5 had the highest ADWG (0.94 ± 0.22 lbs / day), the lowest incidence of abnormal behavior (0%), the second of the lowest manifestation frequencies cough (8.3%), the lowest rate of manifestation of common clinical symptoms (8.3%), the lowest mortality rate (0%), the lowest nasal discharge of PCV2 (8.3%), the second of the lowest levels of average % of lung injuries (0.68 ± 1.15%) and the lowest frequency of manifestation of IHC-positive tissues (16.7%).

In another aspect of the present invention, MPD was determined as 1 ml / 1 dose of a conventional product, which is a partially purified PCV2 ORF2 antigen (vORF2), in a CDCD piglet model at risk of PCV2 infection. Of the three groups, after administration of different levels of vORF2 antigen, group 1 (16 μg vORF2) had the highest level of protection. Group 1 exceeded groups 2 and 3 in terms of ADWG, mean% lung damage and IHC. Groups 1 and 2 (8 μg of vORF2 antigen) were the same with respect to the general clinical symptoms, group 3 (4 μg of vORF2 antigen) had the lowest mortality rate, and all three groups were the same with respect to nasal secretion. In general, vORF vaccines did not work as well as rORF vaccines.

In another aspect of the present invention, the maximum dose efficiency was determined as 2 ml / 2 doses of the conventional killed PCV2 vaccine in a CDCD piglet model at risk of PCV2 infection. Of the seven vaccines evaluated in this study, the killed whole-cell PCV2 vaccine performed the worst. Piglets after administering two doses of the killed whole-cell vaccine PCV2 had the lowest ADWG, the second of the highest levels of abnormal behavior (58.3%), the second of the highest overall frequencies of manifestations of common clinical symptoms (58.3%), the highest mortality rate ( 16.7%), the second of the highest manifestations of nasal discharge (41.7%), the highest average% of lung injuries (9.88 ± 29.2%), the highest incidence of the described lung injuries (75%) and moderate frequency manifestations of positive IHC in tissues (41.7%). However, it was still effective in eliciting an immune response.

In another aspect of the present invention, nasal secretion of PCV2 was evaluated as an efficacy parameter, and previous PCV2 efficacy parameters from previous studies were again confirmed. The results of this study show that nasal secretion of PCV2 occurs after intranasal infection, and that PCV2 vaccines reduce nasal secretion of PCV2 after infection. Moreover, the results of this study and publications in the literature indicate that IHC should also continue to be used to evaluate future trials of the PCV2 vaccine.

Some additional findings from this study are that lymphadenopathy is one of the hallmarks of PMWS. Other hallmarks of PMWS are lymphoid depletion and multinucleated / giant histiocytes. In addition, no adverse events or reactions were detected at the injection site for any of the 7 PCV2 vaccines, and all 7 PCV2 vaccines appeared to be safe when given to young piglets.

EXAMPLE 5

In this example, the efficacy of eight candidate PCV2 vaccines was tested and the parameters of PCV2 infection from previous infection studies after exposure to the virulent strain of PCV2 were again confirmed. One hundred and fifty (150) Caesarean-sectioned, colostrum-free (CDCD) piglets aged 6–16 days were grouped by weight and randomly assigned to 10 groups of equal size. Table 16 describes the overall structure of the study for this example.

Table 16. The overall structure of the study Group Number of piglets Impact Day exposure KLH / ICFA on day 21 and day 28 Virulent PCV2 infection on day 25 PRRSV MLV per day 46 Autopsy on the day 50 one fifteen PCV2 vaccine 1 16 mcg rORF2-IMS 1314 0 and 14 + + + + 2 fifteen PCV2 vaccine 2 16 mcg vORF2-carbopol 0 and 14 + + + + 3 fifteen PCV2 vaccine 3 16 mcg rORF2-carbopol 0 and 14 + + + + four fifteen PCV2 vaccine 2 16 mcg vORF2-carbopol 0 + + + + 5 fifteen PCV2 vaccine 3 4 mcg rORF2-carbopol 0 and 14 + + + +

6 fifteen PCV2 vaccine 3 1 mcg rORF2-carbopol 0 and 14 + + + + 7 fifteen PCV2 vaccine 3 0.25 mcg rORF2-carbopol 0 and 14 + + + + 8 fifteen PCV2 vaccine 4> 8.0 log mcg KV-carbopol 0 and 14 + + + + 9 fifteen Infection controls N / a + + + + 10 fifteen No -
Strict Negative Control Group N / a + - + + vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

The vaccine formulations administered in each group were as follows. PCV2 vaccine No. 1, administered in a 1 × 2 ml dose in group 1, was a high dose (16 μg / 2 ml dose) of the inactivated recombinant antigen ORF2 with IMS 1314 adjuvant (16 μg rORF2 - IMS 1314). PCV2 vaccine No. 2, administered in a 1 × 2 ml dose in group 2, was a high dose (16 μg / 2 ml dose) of partially purified PCV2 ORF2 antigen mixed with VIDO R-1 mixed with adjuvant carbopol (16 μg vORF2 - carbopol ) PCV2 vaccine No. 3, administered in a 1 × 2 ml dose in group 3, was a high dose (16 μg / 2 ml dose) of the inactivated recombinant ORF2 antigen mixed with adjuvant carbopol (16 μg rORF2 - carbopol). PCV2 vaccine No. 4, administered in a 1 × 1 ml dose in group 4, was a high dose (16 μg / 1 ml dose) of partially purified PCV2 ORF2 antigen mixed with VIDO R-1 mixed with adjuvant carbopol (16 μg vORF2 - carbopol ) Vaccine No. 5, administered in a 1 × 2 ml dose in group 5, was a 4 μg / 2 ml dose of inactivated recombinant antigen ORF2 mixed with adjuvant carbopol (4 μg rORF2 - carbopol). PCV2 vaccine No. 6, administered in a 1 × 2 ml dose in group 6, was a 1 μg / 2 ml dose of inactivated recombinant ORF2 antigen mixed with carbopol adjuvant (1 μg rORF2 - carbopol). PCV2 vaccine No. 7, administered in a 1 × 2 ml dose in group 7, was a low dose (0.25 μg / 2 ml dose) of inactivated recombinant ORF2 antigen mixed with carbopol adjuvant (0.25 μg rORF2-carbopol). PCV2 vaccine No. 8, administered in a 1 × 2 ml dose in group 8, was a high dose (titer before inactivation> 8.0 log / 2 ml dose) of the inactivated commonly killed killed VIDO RI PCV2 Struve antigen mixed with carbopol adjuvant ( > 8.0 log KV - carbopol). At day 0, groups 1-8 were treated with the vaccines intended for them. In groups 1-3 and 5-8, secondary injections of their respective vaccines were again administered on day 14. The single dose efficacy of 16 μg of vORF2 - carbopol was tested in group 4, in which secondary injection was not administered on day 14. Adverse events and reactions were examined in piglets. at the injection site after both vaccinations. On day 21, piglets were transferred to the second research center, where groups 1–9 were groups contained in one building, and group 10 was kept in a separate building. All piglets were injected with saucer hemocyanin emulsified with incomplete Freund's adjuvant (KLH / ICFA) on days 22 and 28. On day 25, groups 1-9 were infected with approximately 4 log of virulent PCV2 virus. By 46 days, very few deaths occurred in the control group. In an attempt to immunostimulate the piglets and increase the virulence of the PCV2 infection material, all groups were treated with INGELVAC® PRRSV MLV (live virus modified porcine respiratory reproductive syndrome vaccine) for 46 days.

Blood samples were collected before and after infection for PCV2 serology. After infection, body weight data were collected to determine average daily weight gain (ADWG) and clinical symptom examination data. On the day, 50 of all surviving piglets were opened, documented lesions in the lungs, a quantitative assessment of lung pathology was obtained, and selected tissues were fixed in formalin for immunohistochemical (IHC) analysis to detect PCV2 antigen later.

Materials and methods

This was a partially blind vaccination-feasibility study conducted on CDCD piglets aged 6–16 days per day 0. PCA2 IFA titers in sows for inclusion in the study were ≤1: 1000. In addition, the serological status of the sows came from a known PRRS-negative herd. Sixteen (16) sows were tested for serological status for PCV2, all sixteen (16) had a PCV2 titer of ≤1000, and were transferred to the first study center. One hundred fifty (150) piglets were removed by cesarean section, and they were available for this study for days - 3. On day -3, 150 CDCD piglets in the first study center were weighed, labeled with ear tags, grouped by weight and randomly assigned to groups 1- 10, as indicated in Table 16. above, if any animal satisfying the inclusion criteria was registered for the study and then excluded for any reason, the researcher and the controller consulted to determine the applicability of the data collected for of the animal, in the final analysis. The date of exclusion of registered piglets and the reason for the exception were documented. None of the sows that met the inclusion criteria, selected for the study and transported to the first research center, were not excluded. No piglets were excluded from the study, and no test animals were removed from the study before termination. Table 17 describes the time frame for the key operations of this example.

Table 17. Research operations Day study Valid Dates Research operations -3 4-04-03 Piglets were weighed; examined for health reasons; Randomly assigned to groups; Blood samples were collected -3,
0-21 4-04-03
4-07-03-
5-27-03 General health status and adverse events after vaccination were examined. 0 4-07-03 Introduced appropriate IVP groups 1-8 0-7 4-07-03-
4-14-03 The piglets were examined for reactions at the infection site. fourteen 4-21-03 Secondary administration was performed in groups 1-3, 5-8 of the corresponding IVP; Blood samples were taken from all piglets 14-21 4-21-03-
4-28-03 The piglets were examined for reactions at the infection site. 19-21 4-26-03-
4-28-03 All piglets were treated with antibiotics. 21 4-28-03 Piglets were transported from Sturbe Labs, Inc. to Veterinary Resources, Inc. (VRI) 22-50 4-07-03-
5-27-03 The piglets were examined for clinical signs after infection. 22 4-29-03 Treated groups 1-10 KLH / ICFA

25 5-02-03 Blood samples were collected from all piglets; All piglets were weighed; infected groups 1-9 with PCV2 material for infection 28 5-05-03 Treated groups 1-10 KLH / ICFA 32 5-09-03 Blood samples were collected from all piglets 46 5-23-03 INGELVAC® PRRS MLV was administered in all groups fifty 5-27-03 Blood samples were collected, weighed, and all piglets were dissected; macroscopic lesions were noted; lung damage was assessed; retained fresh and formalin-fixed tissue samples; Completed the intravital phase of the study

After completion of the intravital phase of the study, the pathologist examined formalin-fixed tissues by means of immunohistochemistry (IHC) to detect the PCV2 antigen, PCV2 in blood samples was determined serologically, and the average weight gain (ADWG) from 25 days to 50 days was determined.

In the first research center, animals were kept in individual cages in seven rooms from birth to about 11 days of age (approximately 0 days of the study). All rooms were identical in layout and contained racks with individual stainless steel cages with heated and filtered air, delivered separately to each individual unit. Each room had its own heating and ventilation, thus preventing cross-contamination of air between the rooms. In a second research center, animals were kept in two different buildings. Group 10 (strict negative control group) was kept separately in a converted room for young animals, and groups 1–9 were kept in a converted farrowing pigsty. Each group was kept in a separate pen (14-15 pigs per pen), and approximately 2.3 square feet per piglet was provided in each pen. Groups 2, 4 and 8 were held in three neighboring pens on one side of the aisle, and groups 1, 3, 5, 6, 7, and 9 were held in six neighboring pens on the other side of the aisle. The separation of the groups was performed due to the concerns of the study controller that the vaccines administered to groups 2, 4 and 8 were not completely inactivated. Each paddock was on a raised floor with plastic flooring. The recess under the pens served as a reservoir for excrement and garbage. Each building had its own heating and ventilation systems, with little chance of cross-contamination of air between buildings.

In the first research center, piglets were fed a specially formulated milk diet from birth to about 3 weeks of age. By 21 days (approximately 4 ½ weeks of age), all piglets consumed a solid, specially blended diet. In the second research center, all piglets were fed a custom-made, drug-free, commercial mixed diet suitable for their age and weight, as desired. Water at both research centers was also available at will.

All test piglets were injected with 1.0 ml of NAXCEL®, IM, in changing hips, on days 19, 20 and 21. In addition, piglet No. 11 (group 1) was injected with 0.5 ml of NAXCEL® IM on day 10, piglet No. 13 (group 10) was administered 1 ml of penicillin and 1 ml of PREDEF® 2X on day 10, piglet No. 4 (group 9) was administered 1.0 ml of NAXCEL® IM on day 11, and each of piglets 1 (group 1), 4 and 11 was administered 1.0 ml of NAXCEL® on day 14 for various medical reasons.

At this time, in both research centers, the piglets were monitored by a veterinarian. An examination of the health status of animals was carried out on day -3 and documented in the form of a health examination record. All animals had good health and nutritional status before vaccination, as determined by examination on day 0. All tested animals were examined, were in good health and nutritional status before infection. Skeletons and tissues were disposed of in a burner. The last placement of the test animals was recorded in the protocol of the placement of animals.

On day 0 and 14, piglets recorded in groups 1-3 and 5-8 were injected with 2.0 ml of the prescribed PCV2 1-4 vaccines, respectively, IM in the neck area on the right and left, respectively, using a sterile 3.0 ml syringe with a Luer tip and a 20g × ½ "sterile needle. Pigs in group 4 were injected with 1.0 ml of PCV2 No. 2 IM vaccine in the right neck area using a sterile 3.0 ml syringe with a Luer tip and a 20g × ½ sterile needle. "only for day 0.

On day 22, all test piglets were injected with 2.0 ml KLH / ICFA IM in the left neck area using a sterile 3.0 ml Luer tip syringe and a 20g × 1 sterile needle. On day 28, 2.0 ml KLH was administered to all test piglets / ICFA to the right thigh using a sterile 3.0 ml syringe with Luer tip and a 20g × 1 "sterile needle.

On the day, 25 piglets, recorded in groups 1-9, were injected with 1.0 ml of material for PCV2 infection ISUVDL (3.98 log ₁₀ TCID ₅₀ / ml) IM in the neck on the right using a sterile 3.0 ml syringe with Luer tip and 20g × 1 "sterile needle. An additional 1.0 ml of the same material was injected IN into each piglet (0.5 ml per nostril) using a sterile 3.0 ml syringe with Luer tip and nasal cannula.

On day 46, 2.0 ml of INGELVAC® PRRS MLV, IM was injected into all of the test piglets on the right neck using a sterile 3.0 ml Luer tip syringe and a 20g × 1 sterile needle. PRRSV MLV was administered in an attempt to increase the virulence of PCV2 infection material .

The tested animals were examined daily according to the general state of health and the presence of adverse events on days -3 and 0 days to 21 days. For each piglet, normal or abnormal behavior, breathing, or coughing were quantified. The examinations were documented in the clinical examination protocol. All test piglets were examined from day 0 to day 7, and group 7 was additionally examined from 14 to 21 days according to reactions at the injection site. The average daily weight gain was determined by weighing each piglet on a calibration scale for days -3, 25 and 50, or for a day in which the piglet was found dead after infection. Body weight was recorded in the form of body weight. A body weight of -3 days was used to separate the piglets into groups before randomization. Mass data on day 25 and day 50 were used to determine the average daily weight gain (ADWG) for each pig during these time points. For piglets who died after infection and before 50 days, ADWG was customized to represent ADWG from 25 days to the day of death.

For the serological determination of PCV2, whole pigs were sampled from each vein from the orbital venous sinuses on days -3 and 14. Each piglet was sampled from the orbital venous sinus by introducing a sterile capillary tube into the midline of the palpebral fissure of one of the eyes and removing approximately 3 , 0 ml whole blood in a 4.0 ml serum separation tube (SST). On days 25, 32, and 50, whole venous blood was collected from each anterior vena cava piglet using a sterile 20 g × 1½ "Vacutainer® needle (Becton Dickinson and Company, Franklin Lakes, New Jersey), a needle holder for Vaccutainer® and 13 ml SST. Blood samples at each time point were recorded in a sample collection protocol. Blood samples were allowed to clot, then each SST was centrifuged and serum collected. The collected serum was transferred to a sterile snap-on tube and stored at -70 ± 10 ° C until testing. at a later date. Sonal BIVI-R & D tested the presence of antibodies to PCV2.

In piglets once a day from 22 days to 50 days, clinical symptoms were observed and normal or abnormal behavior, breathing, or coughing were quantified. Clinical examinations were documented in the clinical examination protocol.

Pigs No. 46 (group 1) and 98 (group 9) died in the first study center. Both of these deaths were classified as bleeding deaths, and no autopsy was performed for the two piglets. In the second center of the study, autopsies of pigs who died after infection and up to 50 days were performed, and piglets euthanized on day 50. Any macroscopic lesions were noted, and the percentage of lung lobes with lesions was documented in the form of an autopsy report.

From each of the piglets opened in the second center of the study, according to a sample of tissue from the tonsil, lung, heart, liver, mesenteric lymph node, kidney and inguinal lymph node were placed in a separate container with buffered 10% formalin; at the same time, another tissue sample from the above organs was placed in Whirl-pak® (M-Tech Diagnostics Ltd., Thelwall, UK) and each Whirl-pak® was placed on ice. Each container was labeled accordingly. Sample collection was documented in the form of an autopsy protocol. Formalin-fixed samples and a diagnostic request form were then accepted for IHC testing. IHC testing was carried out according to standard laboratory methods for obtaining samples, sample preparation and glass and staining methods. Fresh samples at Whirl-pak® were sent along with ice packs to the study supervisor for storage (-70 ° ± 10 ° C) and possible future use.

Formalin-fixed tissues were examined by a pathologist to detect PCV2 by IHC and evaluated using the following scoring system: 0 = none; 1 = limited positive staining, few patches; 2 = moderate positive staining, multiple patches; and 3 = profuse positive staining, spread throughout the tissue. For analytical purposes, a score of 0 was considered “negative”, and a score of more than 0 was considered “positive”.

results

The results for this example are shown below. It was noted that piglets No. 46 and 98 died on days 14 and 25, respectively. These deaths are classified as bleeding deaths. Piglet No. 11 (group 1) was suffocating from frequent breathing on day 15. Otherwise, all piglets were normal in behavior, breathing and coughing during this observation period, and no adverse events were detected in any group. After vaccination on day 0, no reactions were detected at the injection site. After vaccination on day 14, seven (7) out of fourteen (14) group 1 piglets (50.0%) had a swelling with a “2” score on day 15. Four (4) out of fourteen (14) in group 1 (28, 6%) still had a swelling with a “2” score on day 16. None of the other groups experienced reactions at the injection site after any vaccination.

The results of average weight gain (ADWG) are presented below in table 18. Piglets No. 46 and 98 who died from bleeding, were excluded from the results of the group. Group 4, which was administered a single dose of 16 μg of vORF2-carbopol, had the highest ADWG (1.16 ± 0.26 pounds / day), followed by groups 1, 2, 3, 5, 6, and 10 with ADWG in the range from 1.07 ± 0.23 pounds / day to 1.11 ± 0.26 pounds / day. Group 9 had the lowest ADWG (0.88 ± 0.29 pounds / day), followed by Groups 8 and 7 with an ADWG of 0.93 ± 0.33 pounds / day and 0.99 ± 0.44 pounds / day , respectively.

Table 18. Generalization of the average daily weight gain in groups (ADWG) Group Impact N ADWG - pounds / day (day 25 - day 50) or with substitution for piglets who died before 50 days one rORF2 - 16 mcg - IMS 1314 2 doses fourteen 1.08 ± 0.30 pounds / day 2 vORF2 - 16 mcg - carbopol 2 doses fifteen 1.11 ± 0.16 pounds / day 3 rORF2 - 16 mcg - carbopol 2 doses fifteen 1.07 ± 0.21 pounds / day four vORF2 - 16 mcg - carbopol 1 dose fifteen 1.16 ± 0.26 pounds / day 5 rORF2 - 4 mcg - carbopol 1 dose fifteen 1.07 ± 0.26 pounds / day 6 rORF2 - 1 mcg - carbopol 2 doses fifteen 1.11 ± 0.26 pounds / day 7 rORF2 - 0.25 mcg - carbopol 2 doses fifteen 0.99 ± 0.44 lbs / day 8 KV> 8.0 log - carbopol 2 doses fifteen 0.93 ± 0.33 lbs / day 9 Infection controls fourteen 0.88 ± 0.29 pounds / day 10 Strict negative controls fifteen 1.07 ± 0.23 pounds / day vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

Serological results for PCV2 are presented below in table 19. All ten (10) groups were PCV2 seronegative at day -3. On day 14, PCV2 titers remained low for all ten (10) groups (in the range of 50-113). On day 25, group 8, which was administered the killed whole-cell viral vaccine, had the highest PCV2 titer (4617), followed by group 2, which was given 16 μg of vORF2 - carbopol, group 4, which was administered in a single dose of 16 μg of vORF2 - carbopol, and group 3, which was injected with 16 μg of rORF2-carbopol, with titers of 2507, 1920 and 1503, respectively. At day 32 (one week after infection), titers for groups 1-6 and group 8 were in the range from 2360 to 7619; while groups 7 (0.25 μg rORF2 - carbopol), 9 (infection control), and 10 (strict negative control) had titers of 382, 129 and 78, respectively. At day 50 (autopsy day), for all ten (10) groups showed high PCV2 titers (≥1257).

On day 25, 32, and 50, group 3, which was administered in two doses of 16 μg of rORF2-carbopol, had higher antibody titers than group 1, which was administered in two doses of 16 μg of rORF2 - EVIS 1314. On day 25, 32 and 50 group 2, which was administered in two doses of 16 μg of vORF2, had a higher titer than group 4, which was administered only one dose of the same vaccine. Groups 3, 5, 6, 7, which were administered with increasing levels of rORF2-carbopol at 16, 4, 1 and 0.25 μg, respectively, had correspondingly decreasing antibody titers on day 25 and 32

Table 19. Compilation of PCV2 titers in IFA in groups Group Impact Day -3 Day 14 ** Day 25 *** Day 32 Day 50 **** one rORF2 - 16 mcg -
IMS 1314 2 doses fifty 64 646 3326 4314 2 vORF2 - 16 mcg - carbopol 2 doses fifty 110 2507 5627 4005 3 rORF2 - 16 mcg - carbopol 2 doses fifty 80 1503 5120 6720 four vORF2 - 16 mcg - carbopol 1 dose fifty 113 1920 3720 1257 5 rORF2 - 4 mcg -
carbopol 1 dose fifty 61 1867 3933 4533 6 rORF2 - 1 mcg -
carbopol 2 doses fifty 70 490 2360 5740 7 rORF2 - 0.25 mcg - carbopol 2 doses fifty 73 63 382 5819 8 KV> 8.0 log - carbopol 2 doses fifty 97 4617 7619 10817 9 Infection controls fifty 53 fifty 129 4288 10 Strict negative controls fifty fifty fifty 78 11205 vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture
* For the purpose of calculation, the titer in IFA ≤100 was designated as the titer “50”; an IFA titer of ≥6400 was designated as an IFA titer of “12800”.
** Day of infection
*** Day Showdown

The results of clinical examinations after infection are presented below. Table 20 contains observations of abnormal behavior, abnormal breathing, coughing, and diarrhea. Table 21 contains the results of a generalization of the general frequency of manifestation of clinical symptoms in groups, and table 22 contains the results of a generalization of the mortality rate from a summary of the mortality levels in groups after infection. The incidence of abnormal behavior, respiration and coughing after infection was low in piglets after administration of 16 μg rORF2-IMS 1314 (group 1), 16 μg rORF2-carbopol (group 3), 1 μg rORF2-carbopol (group 6), 0.25 mcg rORF2-carbopol (group 7), and in piglets in the infection control group (group 9). The frequency of abnormal behavior, respiration, and coughing after infection was zero in piglets after administration of 16 μg of vORF2-carbopol (group 2), a single dose of 16 μg of vORF2-carbopol (group 4), 4 μg of rORF2-carbopol (group 5),> 8 log KV-carbopol (group 8), and in piglets in the strict negative control group (group 10).

The overall incidence of clinical symptoms varied between groups. Piglets after administration of 16 μg of vORF2-carbopol (group 2), a single dose of 16 μg of vORF2-carbopol (group 4), and piglets in the strict negative control group (group 10) had a manifestation rate of 0%; piglets after administration of 16 μg rORF2-carbopol (group 3), and 1 μg rORF2-carbopol (group 6) had a manifestation rate of 6.7%; piglets after administration of 16 μg rORF2-IMS 1314 (group 1) had a total manifestation rate of 7.1%; piglets after administration of 4 μg rORF2-carbopol (group 5), 0.25 μg rORF2-carbopol (group 7), and> 8 log KV vaccines had a manifestation rate of 13.3%; and piglets in the infection control group (group 9) had a manifestation rate of 14.3%.

Overall mortality rates also varied between groups. Group 8, which was given 2 doses of the KV vaccine, had the highest mortality rate of 20.0%; it was followed by group 9, the infection control group and group 7, which were injected with 0.25 μg rORF2-carbopol and which had mortality rates of 14.3% and 13.3%, respectively. Group 4, which was administered a single dose of 16 μg of vORF2-carbopol, had a 6.7% mortality rate. All other groups 1, 2, 3, 5, 6, and 10 had a 0% mortality rate.

Table 20. Summary of observations in groups after infection of abnormal behavior, abnormal breathing, and coughing

Group Impact N Abnormal behavior ¹ Abnormal behavior ² Cough ³ one rORF2 - 16 mcg -
IMS 1314 2 doses fourteen 0/14
(0%) 0/14
(0%) 1/14
(7.1%) 2 vORF2 - 16 mcg - carbopol 2 doses fifteen 0/15
(0%) 0/15
(0%) 0/15
(0%) 3 rORF2 - 16 mcg - carbopol 2 doses fifteen 0/15
(0%) 0/15
(0%) 1/15
(6.7%) four vORF2 - 16 mcg - carbopol 1 dose fifteen 0/15
(0%) 0/15
(0%) 0/15
(0%) 5 rORF2 - 4 mcg -
carbopol 1 dose fifteen 1/15
(6.7%) 1/15
(6.7%) 0/15
(0%) 6 rORF2 - 1 mcg -
carbopol 2 doses fifteen 0/15
(0%) 0/15
(0%) 1/15
(6.7%) 7 rORF2 - 0.25 mcg - carbopol 2 doses fifteen 0/15
(0%) 1/15
(6.7%) 1/15
(6.7%) 8 KV> 8.0 log - carbopol 2 doses fifteen 1/15
(6.7%) 1/15
(6.7%) 0/15
(0%) 9 Infection controls fourteen 1/14
(7.1%) 1/14
(7.1%) 2/14
(14/3%) 10 Strict negative controls fifteen 0/15
(0%) 0/15
(0%) 0/15
(0%) ¹ The total number of piglets in each group for which any abnormal behavior was shown for at least one day
² The total number of piglets in each group for which any abnormal breathing was shown for at least one day
³ The total number of piglets in each group for whom a cough was shown for at least one day

Table 21. Generalization of the overall frequency of clinical symptoms Group Impact N The proportion of piglets with clinical symptoms ¹ Frequency of manifestation one rORF2 - 16 mcg -
IMS 1314 2 doses fourteen one 7.1% 2 vORF2 - 16 mcg - carbopol 2 doses fifteen 0 0,0% 3 rORF2 - 16 μg - carbopol 2 doses fifteen one 6.7% four vORF2 - 16 μg - carbopol 1 dose fifteen 0 0,0% 5 rORF2 - 4 μg -
carbopol 1 dose fifteen 2 13.3% 6 rORF2 - 1 μg -
carbopol 2 doses fifteen one 6.7% 7 rORF2 - 0.25 μg - carbopol 2 doses fifteen 2 13.3% 8 KV> 8.0 log - carbopol 2 doses fifteen 2 13.3% 9 Infection controls fourteen 2 14.3% 10 Strict negative controls fifteen 0 0,0% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture
¹ Total number of piglets in each group for which any clinical symptoms were shown for at least one day

Table 22. Generalization of mortality in groups after infection Group Impact N Dead after infection Mortality rate one rORF2 - 16 mcg -
IMS 1314 2 doses fourteen 0 0,0% 2 vORF2 - 16 mcg - carbopol 2 doses fifteen 0 0,0% rORF2 - 16 mcg - carbopol 2 doses fifteen 0 0,0% four vORF2 - 16 mcg - carbopol 1 dose fifteen one 6.7% 5 rORF2 - 4 mcg -
carbopol 1 dose fifteen 0 0,0% 6 rORF2 - 1 mcg -
carbopol 2 doses fifteen 0 0,0% 7 rORF2 - 0.25 mcg - carbopol 2 doses fifteen 2 13.3% 8 KV> 8.0 log - carbopol 2 doses fifteen 3 20.0% 9 Infection controls fourteen 2 14.3% 10 Strict negative controls fifteen 0 0,0% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

A summary of the average percentage of lung damage and preliminary diagnoses is given in Table 23 below. Group 9, the infection control group, had the highest percentage of lung damage with an average of 10.81 ± 23.27%, followed by Group 7, which was injected with 0.25 μg rORF2-carbopol and which had an average of 6.57 ± 24.74%, group 5, which was administered 4 μg of rORF2-carbopol and which had an average of 2.88 ± 8.88%, and group 8, which was administered the KV vaccine and which had average 2.01 ± 4.98%. The remaining six (6) groups had a lower average percentage of lung damage in the range from 0.11 ± 0.38% to 0.90 ± 0.15%.

Preliminary diagnoses of pneumonia varied between groups. Group 3, which was administered in two doses of 16 μg of rORF2-carbopol, had the lowest percentage of preliminary diagnosis of pneumonia of 13.3%. Group 9, the infection control group, had a 50% preliminary diagnosis of pneumonia, followed by group 10, the strict negative control group, and group 2, which were given two doses of 16 μg of vORF2-carbopol, with 46.7% and 40%, respectively, with a preliminary diagnosis of pneumonia.

Groups 1, 2, 3, 5, 9, and 10 had 0% of the groups with a preliminary diagnosis of PCV2 infection; whereas group 8, which was given two doses of the KV vaccine, had the highest proportion in the preliminary diagnosis group for PCV2 infection, 20%. Group 7, which was administered two doses of 0.25 μg of rORF2-carbopol, and group 4, which was administered a single dose of 16 μg of vORF2-carbopol, had preliminary diagnoses of PCV2 infection in the 13.3% and 6.7% of each group, respectively .

Gastric ulcer was diagnosed only in one piglet in group 7 (6.7%); while other groups remained free of stomach ulcers.

Table 23. Generalization of the average% lung damage and the frequency of preliminary diagnosis in groups Group Impact N The number of piglets with the allocation of at least one day Frequency of manifestation one rORF2 - 16 mcg -
IMS 1314 2 doses fifteen 0 0% 2 vORF2 - 16 mcg - carbopol 2 doses fifteen one 6.7% 3 rORF2 - 16 mcg - carbopol 2 doses fifteen 3 20.0% four vORF2 - 16 mcg - 1 dose carbopol fifteen 2 13.3% 5 rORF2 - 4 mcg -
carbopol 1 dose fifteen 3 20.0% 6 rORF2 - 1 mcg -
carbopol 2 doses fifteen 6 40.0% 7 rORF2 - 0.25 mcg - carbopol 2 doses fifteen 7 46.7% 8 KV> 8.0 log - carbopol 2 doses fifteen 12 80% 9 Infection controls fourteen fourteen 100.0% 10 Strict negative controls fifteen fourteen 93.3% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

A summary of the frequency of IHC positive results in the groups is shown below in Table 24. Group 1 (16 μg rORF2 - IMS 1314) had the lowest frequency in the IHC positive group with 0% pigs positive for PCV2, followed by Group 2 (16 μg vORF2 -carbopol) and group 4 (a single dose of 16 μg vORF2 - carbopol), which have IHC frequencies in the groups of 6.7% and 13.3%, respectively. Group 9, the infection control group, had the highest prevalence of positive IHC with 100% PCV2 positive piglets, followed by group 10, the strict negative control group, and group 8 (KV vaccine), with 93.3% and 80% PCV2 positive piglets, respectively.

Table 24. Generalization of the frequency of positive IHC results in groups Group Impact N The number of piglets with the allocation of at least one day Frequency of manifestation one rORF2 - 16 mcg -
IMS 1314 2 doses fifteen 0 0% 2 vORF2 - 16 mcg - carbopol 2 doses fifteen one 6.7% 3 rORF2 - 16 mcg - carbopol 2 doses fifteen 3 20.0% four vORF2 - 16 mcg - carbopol 1 dose fifteen 2 13.3% 5 rORF2 - 4 mcg -
carbopol 1 dose fifteen 3 20.0% 6 rORF2 - 1 mcg -
carbopol 2 doses fifteen 6 40.0% 7 rORF2 - 0.25 mcg - carbopol 2 doses fifteen 7 46.7% 8 KV> 8.0 log - carbopol 2 doses fifteen 12 80% 9 Infection controls fourteen fourteen 100.0% 10 Strict negative controls fifteen fourteen 93.3% vORF2 = isolated viral ORF2; rORF2 = recombinant expressed in baculovirus ORF2; KV or killed whole cell virus = PCV2 virus grown in a suitable cell culture

Discussion

In this example, seven PCV2 vaccines were evaluated, which included a high dose (16 μg) of rORF2 antigen mixed with IMS 1314 adjuvant, twice administered, a high dose (16 μg) of vORF2 antigen mixed with carbopol adjuvant, administered twice to one group of piglets and twice to the second group of piglets, a high dose (16 μg) of rORF2 antigen mixed with adjuvant carbopol, administered twice, doses of 4 μg of rORF2 antigen mixed with adjuvant carbopol, administered twice, doses of 1 μg rORF2 antigen mixed with adjuvant carbopol, administered twice, low dose (0.25 μg) of rORF2 antigen mixed with carbopol adjuvant, administered twice, and a high dose (> 8 log) of killed whole-cell PCV2 vaccine mixed with carbopol adjuvant. In general, group 1, which was given two doses of 16 μg rORF2 - IMS 1314, was slightly better than groups 2 through 7, which were given vaccines containing different levels of either vORF2 antigen or rORF2 antigen mixed with carbopol adjuvant, and much better than group 8, which was given two doses of the killed whole-cell vaccine PCV2. Group 1 had the third of the highest ADWGs (1.80 ± 0.30 pounds / day), the lowest incidence of abnormal behavior (0%), the lowest incidence of abnormal breathing (0%), and the lowest incidence of coughing (7, 1%), with a low incidence of general clinical symptoms (7.1%), closely adjoined to three other groups by the lowest mortality rate (0%), the second of the lowest degrees of average% lung damage (0.15 ± 0.34 %), the second of the lowest degrees of pneumonia (21.4%) and the lowest frequency of manifestation of IHC-positive tissues (0%). Group 1, however, was only one group in which reactions were detected at the injection site, including 50% of those vaccinated 1 day after the second vaccination. Other vaccines administered in groups 2 through 7 performed better than the killed vaccine and almost as good as the vaccine administered in group 1.

Group 8, which was given two doses of the killed PCV2 vaccine mixed with carbopol adjuvant, had the worst results from all vaccine groups. Group 8 had the lowest ADWG (0.93 ± 0.33 pounds / day), the second of the highest frequencies of manifestation of abnormal behavior (6.7%), the highest frequency of manifestations of abnormal breathing (6.7%), closely adjoined with three other groups at the highest overall incidence of clinical symptoms (13.3%), had the highest mortality rate of all groups (20%), and had the highest proportion of IHC-positive (80%) of all vaccine groups. There was concern that the killed whole-cell PCV2 vaccine might not be completely inactivated before administration in group 8, which may explain the poor results for this group. Unfortunately, certain data were not available to confirm this concern. In general, in the context of this example, the conventionally killed vaccine did not help to reduce PCV2-related disease.

As mentioned earlier, there were no adverse events associated with the test vaccines, with the exception of the vaccine mixed with IMS 1314 adjuvant. Reactions at the injection site were detected in 50.0% of piglets 1 day after the second vaccination with the vaccine formulated with IMS 1314 and 28 , 6% of piglets 2 days after the second vaccination. None of the piglets showed reactions after administration of vaccines with adjuvant carbopol. In any further studies, including piglets vaccinated with vaccines with IMS 1314 adjuvants, the reactions at the injection site should be carefully monitored in piglets.

All piglets were PCV2 seronegative on day-3 and only group 2 had a titer higher than 100 on day 14. On day 25 (infection day), group 8 had the highest titer of antibodies to PCV2 (4619), followed by group 2 (2507 ) With the exception of groups 7, 9 and 10, for all groups showed a strong antibody response to 32 days. By 50 days, for all groups, including groups 7, 9 and 10, showed a strong antibody response.

One of the hallmarks of late stage PCV2 infection and the subsequent development of PMWS is growth retardation of pigs weaned from the sow, and in severe cases weight loss has been noted. Group weight gain is a quantitative way of demonstrating stunted growth or weight loss. In this example, there was not much difference in ADWG between groups. Group 8 had the lowest ADWG of 0.88 ± 0.29 pounds / day, while group 4 had the highest ADWG of 1.16 ± 0.26 pounds / day. In the context of this study, there was no significant difference between the groups to justify the effectiveness of future vaccines for ADWG.

In addition to weight loss, shortness of breath, lethargy, pallor of the skin, and sometimes jaundice are clinical symptoms associated with PMWS. In this example, abnormal behavior, abnormal breathing, and coughing were not often detected for each group. As shown in this study, this infection model and strain for infection did not lead to very strong clinical symptoms and thus, this is not a strict parameter on which the effectiveness of the vaccine can be based.

In general, the mortality rates in this example were not high, and the absence of a high mortality rate in the infection control group imposes restrictions on this parameter in order to base it on the effectiveness of the vaccine. Before 46 days in each of groups 4 and 7, one out of fifteen piglets died, in group 9 two out of fourteen piglets died, and in group 8 three out of fifteen piglets died. Due to the fact that in group 9, the infection control group, no clinical symptoms were found for PCV2, and in this group there were only two deaths by day 46, the pig respiratory reproductive syndrome (PRRSV) MLV vaccine was administered to all piglets on day 46. B earlier studies used INGELVAC® PRRS MLV as an immunostimulant to enhance PCV2-related PMWS disease, and mortality rates in these earlier studies were higher. Two deaths occurred shortly after administration of the PRRS vaccine on day 46 — in group 4 there was one death on day 46 and in group 7 there was one death on day 47 — which may not have been associated with the administration of the PRRS vaccine. By day 50, group 8, which was given two doses of the killed vaccine, had the highest mortality rate (20%), followed by group 9 (infection control) and group 7 (0.25 μg rORF2 - carbopol), with mortality rates of 14 , 3% and 13.3%, respectively. In general, the introduction of the PRRS vaccine in the late-stage infection model in the examination phase in this example did not significantly increase mortality rates.

Macroscopic lesions in piglets with PMWS secondary to PCV2 infection typically involve generalized lymphadenopathy in combination with one or more of the following: (1) interstitial pneumonia with interlobular edema, (2) pallor of the skin or jaundice, (3 ) mosaic atrophic liver, (4) stomach ulcers and (5) nephritis. At autopsy (day 50), jaundice, hepatitis and nephritis were not found for any of the groups. A gastric ulcer was found in one pig in group 7, but lymphadenopathy was not specifically evaluated. Based on the presence of lesions corresponding to PCV2 infection, the three groups had at least one pig with a preliminary diagnosis of PCV2 (PMWS). Group 8, which was given two doses of the killed vaccine, had 20% with a preliminary diagnosis of PCV2, while group 7 and group 4 had 13.3% and 6.7%, respectively, with a preliminary diagnosis of PCV2. At autopsy, the mean% lung damage varied between groups. Groups 1, 2, 3, 4, 6, and 10 had low values of% lung damage, ranging from 0.11 ± 0.38% to 0.90 ± 0.15%. As expected, group 9, the infection control group, had the highest average value of% lung damage (10.81 ± 23.27%). In four groups, the average values of% lung damage were overestimated due to the fact that from one to three piglets in each of these groups had very high lung damage scores. Most lung lesions were red / purple and consolidated. Typically, PMWS-related lung injuries are described as brown and not deformed by interlobular edema. The lung lesions found in this study were either unrelated to PCV2 infection or a second pulmonary infectious agent could be present. In the context of this study, the% degree of lung damage may not reflect the true measurement of the degree of lung infection due to PCV2. Similarly, a preliminary diagnosis of pneumonia may also be excessive. For all piglets with lung injuries, some as small as 0.10%, a preliminary diagnosis of pneumonia was recorded. In this example, there was no significant difference between the groups with respect to macroscopic lesions and% lung damage, on which the effectiveness of the vaccine can be based.

IHC results showed the greatest differences between groups. Group 1 (16 μg rORF2 - IMS 1314) had the lowest positive IHC results for the PCV2 antigen (0%); while groups 9 and 10 had the highest positive IHC results with a manifestation rate of 100% and 93.3%, respectively. Groups 3, 5, 6, and 7, which were injected with 16, 4, 1, or 0.25 μg of rORF2 antigen, respectively, mixed with adjuvant carbopol, had a degree of positive IHC of 20%, 20%, 40%, and 46.7%, respectively . Group 2, which was given two doses of 16 μg of vORF2 mixed with adjuvant carbopol, had a positive IHC of 6.7%, while group 4, which was administered only one dose of the same vaccine, had a degree of positive IHC of 13.3%. Due to the objective nature of this test and the fact that IHC results correlated with expected results, IHC testing is perhaps one of the best parameters for judging vaccine efficacy.

Thus, in one aspect of the present invention, the minimum protective dose (MPD) of the PCV2 rORF2 antigen mixed with the adjuvant carbopol was determined in the piglet CDCD model at risk of PCV2 infection. In each of groups 3, 5, 6, and 7, two doses of rORF2 antigen mixed with carbopol adjuvant were administered, however, the level of rORF2 antigen changed for each group. In each of groups 3, 5, 6, and 7, 16, 4, 1, or 0.25 μg of rORF2 antigen was administered, respectively. In general, a decrease in the rORF2 antigen level decreased the titers of the anti-PCV2 antibody and increased the mortality rate, the average% of lung damage, and the frequency of manifestation of IHC-positive tissues. Of the four groups that were administered with different levels of rORF2 - carbopol, groups 3 and 5, which were given two doses of 16 or 4 μg of the rORF2 antigen, respectively, each had a positive IHC degree of only 20%, and all had similar antibody titers. Overall, based on positive IHC results, the minimum protective dose of rORF2 antigen administered twice was approximately 4 μg.

In another aspect of the present invention, the antigenicity of recombinant (rORF2) and VIDO R-1 (vORF2) PCV2 antigens was evaluated. In group 2, two doses of 16 μg of vORF2 were administered, and in group 3, two doses of 16 μg of rORF2 were administered. Both vaccines were mixed with adjuvant carbopol. Both vaccines were found to be safe and both had a 0% mortality rate. Group 2 had an anti-PCV2 antibody titer of 2507 on day 25, while group 3 had an anti-PCV2 antibody titer of 1503. Group 3 had a lower% lung damage value than group 2 (0.11 ± 0.38% versus 0, 90 ± 0.15%), however, group 2 had a lower incidence of positive IHC than group 3 (6.7% versus 20%). In general, both vaccines showed similar antigenicity, however, vORF2 was associated with slightly better IHC results.

In another aspect of the present invention, the applicability of two different adjuvants (carbopol and IMS 1314) was determined. In both groups 1 and 3, two doses of the vaccine were administered containing 16 μg of rORF2 antigen, but in group 1 the antigen mixed with IMS 1314 adjuvant was administered, while in group 3 the antigen mixed with carbopol adjuvant was administered. Both groups had essentially the same ADWG, essentially the same frequency of clinical signs after infection, the same mortality rate, and essentially the same average% lung damage; however, group 1 had a positive degree of IHC of 0%, while group 3 had a positive degree of IHC of 20%. However, group 3, which was given the vaccine mixed with carbopol adjuvant, had higher IFAT PCV2 titers of 25, 32, and 50 per day than group 1, which was given the vaccine mixed with IMS 1314 adjuvant. In general, although for PCV2 mixed with IMS 1314 adjuvant, they obtained better IHC results; it did not provide an incomparably better protection against PCV2 infection and caused a reaction at the injection site. At the same time, the PCV2 vaccine mixed with carbopol adjuvant acted almost as well as the IMS 1314 adjuvant vaccine, but was not associated with any adverse events.

In another aspect of the present invention, the applicability of ORF2 PCV2 in the form of a product with 1 dose of 1 ml was determined. In both groups 2 and 4, 16 μg of the vORF2 vaccine mixed with carbopol adjuvant was administered on day 0, but in group 2, a second dose was administered on day 14. Group 4 had a slightly higher ADWG and a lower average% lung damage than group 2, but group 2 had higher titers of EFAT PCV2 on days 25, 32 and 50, and a slightly lower incidence of IHC-positive tissues. All other results for these two groups were the same. In general, one dose of vORF2 mixed with carbopol adjuvant acted in the same way as two doses of the same vaccine.

Claims (19)

1. The use of an immunogenic composition that contains at least 2 μg of recombinant PCV2 protein ORF2 to obtain a medicament for inducing an immune response against PCV2, to reduce the severity of clinical symptoms associated with PCV2 infection, or to prevent PCV2 infection, where the drug is administered single dose per pig. 2. The use of an immunogenic composition that contains at least 2 μg of recombinant PCV2 protein ORF2 to induce an immune response against PCV2, to reduce the severity of clinical symptoms associated with PCV2 infection, or to prevent PCV2 infection by administering a single dose of the pig composition. 3. The use according to claim 1 or 2, wherein said recombinant PCV2 ORF2 protein is obtained by allowing infection of susceptible cells in culture with a recombinant viral vector containing the PCV2 ORF2 DNA coding sequence, where the PCV2 ORF2 protein is expressed by a recombinant viral vector, followed by isolation of said protein PCV2 ORF2. 4. The use of claim 1 or 2, wherein said recombinant PCV2 ORF2 protein is a PCV2 ORF2 protein expressed by recombinant baculovirus. 5. The use of claim 1 or 2, wherein said immunogenic composition comprises an inactivated baculovirus and a cell culture supernatant. 6. The use of claim 3, wherein said viral vector is inactivated by the addition of cyclized binary ethyleneimine (BEI). 7. The use of claim 6, wherein said BEI was neutralized with sodium thiosulfate. 8. The use according to claim 1 or 2, where the specified drug or composition contains an adjuvant. 9. The use of claim 8, wherein said adjuvant is selected from the group consisting of acrylic acid polymers or methacrylic acid polymers. 10. The use of claim 8, wherein said adjuvant is a carbomer. 11. The use of claim 10, wherein said carbomer is a carbopol. 12. The use according to any one of paragraphs. 8-11, where the specified adjuvant contains from about 500 μg to about 5 mg of carbopol per dose. 13. The use according to claim 1 or 2, wherein said immunogenic composition comprising recombinant PCV2 ORF2 protein contains from 4 μg to 200 μg of recombinant PCV2 ORF2 protein per dose. 14. The use of claim 1 or 2, wherein said immunogenic composition comprising a recombinant PCV2 ORF2 protein is stable for 24 months. 15. The use according to claim 1 or 2, wherein said drug or composition is administered together with an immunogenic composition that comprises a porcine respiratory reproductive syndrome (PRRS) antigen. 16. The use of claim 15, wherein said PRRS antigen is an antigen included in IngelVac PRRS MLV. 17. The use according to claim 15 or 16, wherein said drug or composition is administered in a single dose per pig to prevent clinical signs and manifestations of PCV2 disease, where the pig has PRRS infection. 18. The use of claim 1 or 2, wherein said drug or composition is a vaccine. 19. The use of claim 1 or 2, wherein said immune response is a protective immune response or therapeutic immune response.

Images